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1. INTRODUCTION 
 
Amongst human diseases caused by pathogen microorganisms, viral pathogens play a 
significant part. From clinical point of view, a viral infection can follow different patterns in 
time. An acute infection generally means that the infected individual shows symptoms which 
last a short period – generally few days/weeks – and after that the infective virus is eliminated 
completely by the host´s immune system. A chronic or persistent infection in general can be 
defined as an infection that is present in a given individual for a long time interval. The 
presence of the virus can be theoretically equilibrial, increasing, decreasing or intermittent. 
However, these clinical aspects describe only the time course but does not define the under 
lying mechanisms behind these events. It is important to notice that the same virus can cause 
divergent patterns in different individuals [1]. 
On the cellular level a viral infection can be abortive when some viral components are 
synthesized but no infective virus is assembled and/or released. An infection is defined 
productive when new infectious viruses are produced. This results generally in the death of 
the host cell while a large amount of the newly formed viruses are spread towards the 
surroundings and stand ready for a new infection. This type of infection called lytic infection 
results in the lysis of infected cells due to production of viral progeny. The vast majority of 
the viruses possess only this lytic life cycle, the best examples are the influenza viruses 
causing seasonal cold and the rotaviruses causing gastrointestinal infections [1]. 
However, there are some viral families and species which have the ability to maintain 
a different route in the lifecycle. In this case there is no immediate lysis of the host cells. The 
viral genome can exist in the host cell for a longer period of time, sometimes for a lifetime 
and can persist even during the host cell´s replication. The characteristic hallmark of this type 
of viral cycle is the reversibility where under certain circumstances the expression of the viral 
genome can be activated resulting in the productive lytic cycle. This different way in the life 
cycle called latent (dormant) life cycle or infection [2]. The establishment of this latent 
infection depends on various factors of the host, including the immunological status which is 
crucial in determining whether latency shall be the outcome of the primary infection, as well 
as how often a probable subsequent reactivation occurs. 
The clinical and epidemiological significance of viral latency is highly important since 
this type of infection serves as potential reservoir from which dissemination of the pathogen 
to a new host can occur. On the other hand, such infections could play a role in the 
development of some human malignant and benign tumors and thirdly, because the 
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reactivation of the latent virus might cause acute or chronic progressive disorders in the 
original host [2].  
This type of ―carrier state‖ can take different forms. During latency, the viral genome 
can exist as a provirus integrated in the host genome, called proviral latency. In this form of 
latency the viral genome does not replicate directly, but is passively duplicated when the host 
cell divides. The proviral latency appears frequently in cells with the potential for persistent 
proliferation [3]. Another form of latency is known as the episomal latency, where viral genes 
are floating in the cytoplasm or in the nucleus of the host cell as distinct objects and the 
genetic material can form either linear or circular plasmid structures without the integration 
into the genome of the host cell. The episomal latency can occur even in cells with limited 
self-renewing potential and long life expectancy. Both types of latency have advantages and 
disadvantages for the virus. In case of proviral latency, the passive replication of the viral 
genome is beneficial but during the entry into the nucleus the viral genome must face and 
avoid several defense mechanisms that are activated against it by the host cell. During 
episomal latency the effect of dilution could represent a problem in proliferating cells and 
vital genes are more exposed to ribozymes and to the antiviral defensive pathways of the host 
in the cytoplasm and/or in the nucleoplasm. 
The possible consequences of latency show divergent patterns. The most common 
form of the outcome is the reactivation following different, yet not clearly characterized 
activator signals (i.e. stress, sunlight) to cause an acute infection and production of viral 
progeny. A less frequent but more severe consequence is the transformation of the latently 
infected cell which results in a virus induced formation of malignant or benign tumors. The 
transformation can be caused by viral gene products which may exert their effect by 
interfering with particular cellular proteins or by insertional mutagenesis [4]. Some of the 
most extensively studied virus families known to maintain latency include Adenoviridae, 
Parvoviridae, Retroviridae, Papillomaviridae, Polyomaviridae and Herpesviridae among 
others.  
The family of Herpesviridae forms a large and diverse group that includes a 
considerable number of animal viruses. Herpesviruses can cause infections in vertebrates from 
catfish to humans. Furthermore one species has been discovered in invertebrates (Pacific 
oyster) [5]. Herpesviridae show a broad range of pathogenic properties and can cause from 
mild to life-threatening disorders. Based on their biological properties the family of 
Herpesviridae can be further divided into the three subfamilies of Alphaherpesvirinae, 
Betaherpesvirinae, and Gammaherpesvirinae [5, 6].  
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Herpesviruses are defined based on morphological criteria. They share a common 
structure of an icosahedral capsid, containing 162 capsomeres, the tegument which is a layer 
consisting of 22 proteins that surrounds the capsid and a lipid bilayer envelope derived from 
the host cell membrane in which most cell proteins have been replaced by viral membrane 
proteins. As a core they contain a large, linear, double-stranded DNA genome [6, 7] (Fig. 1). 
 
 
 
 
Figure 1. The schematic morphology and structure of herpes viruses [8]. 
 
 
The herpes simplex viruses (HSV): type-1 (HSV-1) and type-2 (HSV-2) belong to the 
Alphaherpesvirinae subfamily of the Herpesviridae family, which are defined by their ability 
to form a relatively short reproductive cycle, rapidly spread in culture, efficiently destruct 
infected cells and by the capacity to establish latent infections primarily – but not exclusively 
– in sensory ganglia [9].  
The HSV-1 – which was the subject of our investigations – is a neurotropic virus that 
establishes latency in sensory neurons innervating the site of primary infection and has the 
capacity to sustain a life-long latent infection and it can also be reactivated from those neurons 
in a periodical manner [10].  
Regarding HSV-1 the primary site of infection is generally the oronasal mucosa, the 
primary infection is often acquired in early childhood. The infection is frequently 
asymptomatic, but it may present as vesicles on the mucosa and finally form ulcers at the site 
of the infected area [11, 12]. Following a productive infection of the epithelial cells, the virus 
enters the terminal axons and the nucleocapsid is transported to the nucleus of the neuron by 
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retrograde axonal transport. Once the virus reaches the ganglia where the bodies of the 
neurons reside either lytic or latent pathway of viral gene expression is triggered [13] (Fig. 2).  
 
 
 
 
Figure 2. Schematic representation of HSV latent infection and reactivation [14]. 
 
 
Not all of the neurons are equally susceptible in the sensory ganglia to productive 
infection and specific types of neurons are more likely to harbor latent HSV- infection based, 
in part, on the differential presence of regulatory RNAs or regulatory proteins [15, 16]. 
Rarely the ganglionitis is followed by herpes simplex encephalitis (HSE), which is the 
most common fatal sporadic encephalitis. HSE is characterized by severe destruction of the 
frontal and the temporal lobe with the adjacent structures, including the amygdala and the 
hippocampus. If left untreated, the mortality rate is as high as 70% with a high rate of 
neurological sequelae [17, 18]. HSV-1 DNA is detectable at a relatively high frequency at 
various sites of the adult human central nervous system (CNS) including the brainstem, 
olfactory bulbs and the temporal lobe [19-22], although it is not clear whether the virus can 
get reactivated in the CNS.  
During latent HSV infection in the trigeminal ganglia (TG), there is little detectable 
viral protein and infectious virus production [20, 23]. HSV transcripts during latency are 
restricted to neurons, with in situ hybridization signals that are strongest over nuclei [24-26]. 
Abundant transcription from the viral genome appears to be restricted to the latency-
associated transcripts (LATs) that map to repeat sequences flanking the unique long region 
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[24-27]. Interestingly, HSV latency in human TG is associated with chronic inflammation 
[28]. It is unknown whether the latent HSV-1 infection itself or the repeated reactivation 
events in the human TG are behind the significant injury of the peripheral nervous system 
characterized by even neuronal loss. 
Virus mediated oncolytic therapy including the application of HSV-1, is a promising 
novel modality of tumor therapy with potential usefulness against a wide variety of 
malignancies [29-33]. Oncolytic HSV-1 therapy is dependent on virus replication in tumor 
cells and is augmented by host antiviral and infection-induced anti-tumor immune responses 
[34-37]. In spite of significant progress, oncolytic virotherapy faces significant challenges. 
Although traditional two-dimensional (2D) monolayer cultures of many types of tumor cells 
are efficiently destroyed by a variety of HSV-1 vectors in vitro, tumor destruction is often 
incomplete in vivo [29, 34]. Factors limiting the effectiveness of HSV-1 oncolytic therapy in 
vivo remain incompletely understood. However, observations indicate that potential problems 
include the impairment of intratumoral virus spread by the extracellular matrix (ECM), 
decreased expression of viral entry receptors by different tumor cell populations, activation of 
intracellular tumor defenses to viral infection, and quick virus clearance by the host immune 
system [34, 38-41]. It is clear that many aspects of the complex virus–host interactions that 
determine the effectiveness of HSV-1 oncolytic therapy are difficult to impossible to study in 
traditional 2D tissue culture systems.  
The behavior of cells in vivo is controlled by their interactions with neighboring cells 
and with the ECM [42-44]. Cancer cells grown in three-dimensional (3D) cultures in a 
polymeric ECM closely mimic the biology of tumor development in vivo and numerous 
studies indicate that 3D cultures are superior to traditional 2D monolayer cultures for studies 
of key cellular behaviors such as differentiation, proliferation, invasion, and apoptosis [45-
48]. Cancer cells grown in 3D culture are more resistant to chemotherapeutic agents and 
radiation than cells in 2D culture and 3D tumor cell cultures are useful for preclinical 
evaluation of the cytotoxic effect of anticancer agents [46, 48, 49]. It is well established that 
multiple cell types within individual tumors have differential sensitivities to drugs. Although 
3D cultures provide an excellent experimental system to study mechanisms of tumor cell 
resistance to drugs and radiation, very few studies have used 3D tumor cell cultures in the 
context of viral oncolytic therapy [50-52]. Earlier work in our laboratory indicated that 3D 
cultures of uveal melanoma cells show increased resistance to HSV-1 relative to 2D cultures 
[52]. Specifically, destruction of 95% of tumor cells in 3D cultures occurred several days later 
than in 2D cultures after HSV-1 inoculation. These findings suggested that HSV-1 inoculation 
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of 3D uveal melanoma cultures could provide a useful model to study mechanisms of ECM-
mediated tumor resistance to HSV-1 oncolytic therapy.  
The goal of our work was to investigate the effect of the HSV-1 latent infection using 
two model systems. 
First, we examined the role of the HSV-1 latent infection in mouse TG-s. Since HSV-1 
latent infection is relatively common in the bipolar neurons in peripheral ganglia we aimed to 
explore the significance of the latent infection and anticipated chronic progressive alterations 
in mean neuron diameter, mean neuron nucleus diameter, TG volume, and mean number of 
neurons per TG. Using morphometric studies we tested whether HSV-1 latent infection has an 
effect on those above mentioned quantitative indicators in healthy adult mice. Studies have 
shown chronic behavioral and neurological deficits and chronic pain in these animals [53-59] 
but chronic progressive quantitative alterations remained poorly understood. Therefore we 
performed in vivo studies using mice to determine the effect of HSV-1 latent infection on 
mean neuron diameter, mean neuron nucleus diameter, TG volume, and mean number of 
neurons per TG.  
Our second aim was to explore virus resistance of distinct tumor cell subpopulations in 
3D tumor cell cultures and the mechanisms of ECM-mediated virus resistance of tumor cells. 
So far very few studies have used 3D tumor cell cultures in the context of viral oncolytic 
therapy. These studies have indicated that tumor cells grown in 3D cultures are also more 
resistant to viral, including HSV-1 and adenovirus-mediated oncolytic therapy, than cells 
grown in 2D culture [46, 48]. Therefore we performed in vitro studies using HSV-1 and uveal 
melanoma cells in 2D and 3D cultures to identify any differences in growth pattern and the 
outcome of the HSV-1 infection. 
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2. AIMS 
 
 
2.1 To investigate the HSV-1 latency and the consequent quantitative alterations on 
morphologic level using in vivo model 
 
 
 To examine the effect of latent HSV-1 infection on mean neuron diameter, neuronal 
nucleus diameter, neuron density and neuron number in trigeminal ganglia derived 
from adult BALB/c mice in association with neuronal injury. 
 
 
2.2 To explore HSV-1 latency in tumor cells and the effect of extracellular matrix 
concerning latently infected tumor cells 
 
 
 To explore whether 3D tumor cell cultures can be used to identify morphologically 
distinct tumor cell populations that have increased resistance to HSV-1. 
 
 To examine whether 3D tumor cell cultures can be used to learn about mechanisms of 
ECM mediated tumor cell resistance to HSV-1 oncolytic therapy. 
 
  
14 
3. MATERIAL AND METHODS 
 
3.1 Investigation of HSV-1 latency and the consequent quantitative alterations on 
morphologic level using in vivo model 
 
3.1.1 Viruses 
 
Wild-type HSV-1 strain 17+ having non-syncycial plaque morphology [60] was 
obtained from Nigel Fraser (University of Pennsylvania, Philadelphia, PA). Virus stocks were 
propagated in complementing cell lines and stored at -80 ºC. Yields of infectious virus titer 
(P.F.U. ml
-1
) were determined by plaque assay in baby hamster kidney (BHK) 21 clone 13 
cells. 
 
3.1.2 Animals 
 
Female BALB/c mice (obtained from Harlan Laboratories, Indianapolis, IN) were bred 
and raised in conventional animal housing. Animal husbandry and experimental procedures 
were performed in accordance with NIH Public Health Service policy and approved by the 
Vanderbilt University School of Medicine Institutional Animal Care and Use Committee. 
 
3.1.3 Inoculation of mice 
 
Four to six-week-old female BALB/c mice were inoculated with 1 x 10
5
 plaque-
forming units (P.F.U.) of HSV-1 17+ per eye after superficial corneal scarification with a 
sterile hypodermic needle under Metofen anesthesia. Control mice were inoculated with an 
equivalent volume of sterile tissue culture medium using the same inoculation technique 
(mock infection). Mice were followed daily for signs and symptoms of disease. Groups of 
mice consisting of five randomly chosen HSV-1-infected or mock-infected mice per treatment 
were euthanized at 1, 12 and 31 weeks after inoculation (at 5, 17 and 35 weeks of age) and TG 
were aseptically removed. TG were excised by cutting the trigeminal root at its entrance into 
the brainstem, the mandibular branch at least 1 mm distally to the ganglion and the maxillary 
branch at the level of the orbital fissure. Tissues were fixed in paraformaldehyde–lysine–
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periodate fixate and embedded in paraffin. Before the final embedding step, TG were 
randomly rotated along their longitudinal axis, embedded in paraffin and sectioned. Multiple 
sections encompassing the complete thickness of the tissue blocks were processed for 
hematoxylin and eosin staining for histologic evaluation, immunohistochemistry, in situ 
hybridization and morphometric studies. 
 
3.1.4 Immunohistochemical detection of HSV-1 proteins 
 
Multiple 6-μm-thick tissue sections derived from representative portions of the 
paraffin-embedded TG tissues were deparaffinized with xylene and dehydrated through a 
series of graded ethanols. Endogenous peroxidase activity was quenched using a 0.3% H2O2-
methanol bath followed by several washes with phosphate buffered saline (PBS). HSV-1 
antigens were detected using a 1:1000 dilution of a polyclonal anti-HSV-1 antiserum raised in 
a rabbit (DAKO). Tissue sections were incubated with primary antibody at 43°C for 32 
minutes before the addition of biotinylated anti-rabbit immunoglobulin secondary antibody, 
avidin-horseradish peroxidase, and 3,3'-diaminobenzidine tetrahydrochloride (0.04%) in 
0.05M Tris-HCL (pH 7.4) and 0.025% H2O2 as a chromogen (Ventana Medical Systems). 
Before staining, the binding of secondary antibodies and conjugates was blocked by 
appropriate reagents provided by the manufacturer. 
 
3.1.5 In situ hybridization for HSV-1-LAT gene expression 
 
In situ hybridization was performed using a nick-translated 
35
S-labeled DNA probe 
specific for HSV-1 latency-associated transcript (LAT) (Bst2±Bst2 fragment) and 6-μm-thick 
tissue sections [61]. Prior to hybridization, 
35
S-labeled nick-translated DNA probes were 
denatured in a boiling water bath for 5 min, cooled on ice, and diluted with hybridization mix 
(2x saline-sodium citrate (SSC) [lx SSC is 0.15 M NaCl plus 0.015 M sodium citrate], 1 mM 
Tris, pH 7.4, 1 mM EDTA, lx Denhardt solution [0.02% polyvinylpyrrolidone, bovine serum 
albumin, and Ficoll], 10% dextran sulfate, 45% formamide, and 100 mg of polyadenylic acid, 
1 mg of mouse brain RNA, and 1 mg of mouse brain DNA per ml). The probe concentration 
was adjusted to contain 1 ng of DNA per 5 μl (ca. 105 cpm per tissue section). The 
hybridization mixture including probe was heated for 30 seconds at 100 °C and cooled on ice; 
10 mM dithiothreitol was added, and the complete mixture was prehybridized at 45°C for at 
least 1 h. Portions of the prehybridized probe solution (5 µl) were placed on tissue sections 
16 
and covered with baked, siliconized cover slips and paraffin oil. After hybridization at 50°C 
for 48 to 65 h, the paraffin oil was removed by two 5-min incubations in chloroform. Cover 
slips were removed by gently shaking the slides in wash solution, and non-hybridized probe 
was removed by extensive washing for 2 days at 37°C in 10 mM Tris-HCl, pH 7.4/2x 
SSC/50% formamide/1 mM EDTA followed by 1 h at 55°C in 2x SSC, then rinsed in 2x SSC, 
and dehydrated in graded ethanol solutions containing 300 mM ammonium acetate. Following 
dehydration in ethanol ammonium acetate (0.3 M), slides were dipped in NTB2 nuclear track 
emulsion (Kodak) that was diluted 1:1 with 0.6 M ammonium acetate. After 2 to 4 days of 
exposure at 4°C, slides were developed with D19 (Kodak) and stained with hematoxylin and 
eosin. The specific activities of the nicktranslated 
35
S-labeled probes were 1 x 10
8
 to 2 x 10
8
 
cpm/µg. 
 
3.1.6 Determination of mean neuron diameter, neuron nucleus diameter, neuron density, TG 
volume, and neuron number per TG 
 
For the determination of mean neuron diameter and mean neuron nucleus diameter, 
multiple 6-μm-thick tissue sections derived from representative portions of the paraffin-
embedded TG tissues were stained with hematoxylin, scanned at 200x magnification using the 
ImageScope® System (Aperio Technologies, Inc.) and analyzed with the aid of Aperio image 
analysis software. The largest diameter and the largest nuclear diameter of 100 randomly 
chosen neurons in each TG were measured manually by an observer blinded to the nature and 
time of inoculation. For each time point and treatment group, measurements were made for 7 
to 12 TG sections derived from five mice yielding 700 to 1200 measurements per group. 
Mean neuron diameter and neuronal nucleus diameter and standard deviations were calculated 
for each treatment type (HSV-1-inoculated or mock-inoculated) and each time point (1, 12 
and 31 weeks after inoculation). 
For neuronal cell density measurements, multiple 20-μm-thick sections derived from 
representative portions of the paraffin embedded TG tissues were cut, stained with 
hematoxylin and viewed using a 60x objective under an Olympus BH-2 microscope (Olympus 
Optical Co. Ltd.; magnification: 600x). For each time point and treatment group (infected or 
mock), five TG (randomly selected left or right) from five mice were examined using at least 
three sections of each TG. Neurons were identified by morphology based on the detection of 
nucleoli and Nissl substance [62]. Neuronal cell density determinations were made with the 
aid of image analysis software (ImageJ, Research Service Branch, National Institute of Mental 
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Health, Bethesda, MD, USA), digital video camera (Sony) and a computer system according 
to a published stereological optical dissector method [62]. The dimensions of the dissector 
used were 50 x 50 μm in the x- and the y-axis. The guard area (the top and bottom of the 
histological section in which neurons were not counted to avoid errors) was 5 μm; the optimal 
dissector’s height was 15 μm. Nuclei were used as counting units. Neuronal density, that is 
the number of neurons per unit volume of TG (neurons per volume, nv), was determined with 
an optical dissector method using Tandrup’s review concerning dorsal root ganglion as a 
guiding principle [62]. The total value of nv for a TG was then determined from: 
 
nv=    
 Ʃ𝑄
𝑝∙Ʃ𝑎 𝑓𝑟𝑎𝑚𝑒  ∙ℎ
 
 
where ΣQ- is the sum of the dissector neurons in the total dissector volumes, a(frame) is the area 
of the counting frame, h is the height of the optical dissector and p is the number of points per 
dissector. Neuron density was determined for each examined TG separately, and mean neuron 
density and standard deviation per treatment group was then calculated.  
The volume of TG was calculated using image analysis software (ImageJ) and digital 
video camera (Sony) to draw manually the contour of each analyzed TG section at a 
magnification of 5x and to measure automatically its area in mm
2
. One of every 10 sections 
derived from the whole thickness of the TG was analyzed. The total volume of ganglia was 
calculated by multiplying the surface area by the thickness of the section and by the number 
of sections included in the interval between the analyzed sections and summarizing the 
calculated volumes for the whole TG. Mean TG volume and standard deviation for each 
treatment group (HSV-1-inoculated or mock-inoculated and 1, 12 and 31 weeks after 
inoculation) was then calculated. 
The number of neurons per TG was calculated based on neuron density and TG 
volume as follows: N = nv x V, where N corresponds to neuron number per TG, nv stands for 
neuron density and V for TG volume. Calculation was performed separately for five TG in 
each treatment group. Mean neuron number per TG and standard deviation for each treatment 
group (HSV-1-inoculated or mock-inoculated and 1, 12 and 31 weeks after inoculation) was 
then calculated. 
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3.1.7 Statistical analyses 
 
Statistical analyses were performed with the STATISTICA software (version 8.0) for 
Windows. Normality was tested using the Kolmogorov–Smirnov test. All variables were 
distributed normally. Homogeneity of variance was determined using F-test and Levene’s test 
was considered violated when this test yielded p < 0.05. All variances were homogeneous. 
Data were assessed using independent samples T-test and repeated measures analysis of 
variance (ANOVA) followed by Scheffe’s post-hoc test. Differences between the means were 
considered statistically significant if p < 0.05. The results are expressed as means ± standard 
deviation (SD) values. 
 
3.2 Investigation of HSV-1 latency in tumor cells and the effect of extracellular matrix 
concerning latently infected tumor cells 
 
3.2.1 Viruses 
 
Wild-type (wt) HSV-1 strain KOS and recombinant HSV-1 strain K26GFP was 
provided by P. Desai (Johns Hopkins University, Baltimore, MD, USA). Jellyfish green 
fluorescence protein (GFP) was fused in-frame with the UL35 ORF generating the K26GFP 
virus whose capsids express GFP [63]. Cells infected with HSV-1 strain K26GFP exhibit 
punctate nuclear fluorescence at early times in the replication cycle and at later times during 
infection, a generalized cytoplasmic and nuclear fluorescence, including fluorescence at the 
cell membranes can be observed [63]. K26GFP was shown to grow in cell culture as well as 
wild type (wt) virus [63]. Virus stocks were propagated in complementing cell lines and 
stored at -80 ºC. Yields of infectious virus titer (P.F.U. ml
-1
) were determined by plaque assay 
in Vero cells. 
 
3.2.2 Cells 
 
Human primary uveal melanoma cells of low (OCM1) and high (C918) invasive 
potential were provided by Robert Folberg (University of Illinois at Chicago, Chicago, IL, 
USA). OCM1 and C918 cells were maintained in Eagle’s Minimal Essential Medium 
(EMEM; BioWhittaker Inc.) supplemented with heat inactivated 15% fetal bovine serum 
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(FBS; Fisher) and 100 mg l
-1
 of penicillin/streptomycin (P/S) without the addition of 
exogenous extracellular matrix (ECM) molecules or growth factors. 
 
3.2.3 Two-dimensional and three-dimensional uveal melanoma cultures 
 
Melanoma cells were grown on six-well plates in EMEM either in the presence (three-
dimensional; 3D cultures) or in the absence (two-dimensional; 2D cultures) of ECM rich in 
laminin (Matrigel, BD Biosciences). For 3D cultures, Matrigel was poured onto tissue culture 
plates to a depth of approximately 0.2 mm followed by polymerization for 1 h at 37 °C before 
placement of melanoma cells on the Matrigel surface. Cultures were incubated in repeatedly 
refreshed culture medium for up to 4 weeks and observed daily under an inverted microscope 
(Leica). 
 
3.2.4 Determination of susceptibility of uveal melanoma cells to wt HSV-1 (KOS) and HSV-1 
K26GFP-mediated destruction in 2D and 3D cultures 
 
C918 and OCM1 uveal melanoma cells were grown on six-well tissue culture plates in 
the presence (3D cultures) or absence of Matrigel (2D cultures). After 3-4 days, when in the 
3D cultures C918 cells formed prominent vasculogenic mimicry patterns and OCM-1 cells 
formed cell aggregates on the Matrigel surface and both cell lines showed invasion of tumor 
cells into the Matrigel matrix, the tissue culture medium was removed and one of the 
following inocula was gently placed on the surface of the cultures: (i) 0.5 ml of sterile PBS 
(mock infection); (ii) wt HSV-1 (strain KOS) with a calculated multiplicity of infection 
(M.O.I.) of 0.5 plaque forming units (PFU) per cell diluted in PBS to a final volume of 0.5 ml; 
(iii) HSV-1 K26GFP with a calculated M.O.I. of 0.5 PFU per cell diluted in PBS to a final 
volume of 0.5 ml. After incubation for 1 h, the original inocula were removed and fresh tissue 
culture medium (3 ml) was added to each well and further incubated in repeatedly refreshed 
culture medium for up to 4 weeks. During this 4-week period, cultures were observed daily 
under an inverted fluorescence microscope (Leica) for evidence of viral cytopathic effects and 
green fluorescent protein (GFP) expression. The day when at least 95% of the melanoma cells 
were destroyed was noted. Cell death was confirmed by the uptake of the charged cationic dye 
Trypan blue (0.2%) by ˃95% of residual cells after incubation of cultures with Trypan blue 
(0.2%) for 10 min at 37 °C. 
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3.2.5 Determination of HSV-1 spread through Matrigel 
 
C918 and OCM1 uveal melanoma cells were grown on 12-well tissue culture plates in 
monolayers (2D cultures). When the cultures reached approximately 70% confluency, culture 
media were removed and either 0.5 ml of a 1:1 mixture of PBS and Matrigel or 0.5 ml of PBS 
was layered on the cells. Cultures were then incubated at 37 °C for 1 h to allow Matrigel to 
polymerize and form an approximately 1 mm thick layer matrix on the cells. Next, cultures 
were either inoculated with 0.5 ml HSV-1 K26GFP diluted in PBS to a calculated M.O.I. of 
0.5 PFU per cell or were mock infected with 0.5 ml PBS by gently layering these solutions on 
the cultures making sure that the Matrigel surface was not violated. After further incubation at 
37 °C for 1 h, additional 2 ml of fresh tissue culture media was added to each well. Cultures 
were then further incubated for up to 2 weeks at 37 °C with fresh culture medium added to the 
cultures every 2 days. During this 2-week period, cultures were observed regularly under an 
inverted fluorescence microscope (Leica) for evidence of GFP expression.  
 
3.2.6 Placement and culturing of earlier HSV-1 inoculated uveal melanoma cells in 2D or 3D 
environments 
 
C918 and OCM1 uveal melanoma cells were grown on 12-well tissue culture plates in 
monolayers (2D cultures). When the cultures reached approximately 70% confluency, culture 
media were removed and the cells were exposed at 37 °C to one of the following inocula: (i) 
0.5 ml of sterile PBS (mock infection) or (ii) HSV-1 K26GFP with a calculated M.O.I. of 0.5 
P.F.U. per cell diluted in PBS to a final volume of 0.5 ml. After incubation for 1 h, the 
original inocula were removed and the monolayers were washed in sterile PBS twice and 1 ml 
of sterile PBS was added to each well. Cells were than scraped off using sterile, disposable 
cell scrapers. Cell suspensions were than centrifuged and cell pellets were resuspended in 
culture medium. Equal volumes (0.25 ml) of the cell suspensions were then used to either 
establish new 2D cultures in 12-well tissue culture plates or 3D cultures as follows. For 3D 
cultures, Matrigel was poured onto tissue culture plates to a depth of approximately 0.2 mm 
followed by polymerization for 1 h at 37 °C. Cell suspensions of HSV-1 K26GFP or mock-
infected uveal melanoma cells were mixed with Matrigel 1:1 (0.25:0.25 ml) and poured on the 
Matrigel-coated wells. Finally, 2 ml of fresh culture medium was added. 2D and 3D cultures 
were then further incubated for up to 4 weeks at 37 °C with fresh culture medium added to the 
cultures every 2 days. During this 4-week period, cultures were observed regularly under an 
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inverted fluorescence microscope (Leica) for evidence of GFP expression and the percentage 
of GFP-expressing cells was determined by counting the number of GFP-positive and GFP-
negative cells in 16 high power microscopic fields for each studied type of treatment at 
selected time points. 
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4. RESULTS 
 
4.1 Investigation of HSV-1 latency and the consequent quantitative alterations at 
morphologic level using in vivo model  
 
4.1.1 Characterization of TG tissues derived from mice at 1, 12 and 31 weeks following 
corneal HSV-1 inoculation 
 
To obtain TG tissues at various stages of HSV-1 infection, mice were inoculated on 
the cornea with either HSV-1 or sterile tissue culture medium. A minority of HSV-1-infected 
mice demonstrated signs of encephalitis (agitation or paralysis), and 13% of the animals died 
within 3 weeks of infection. Animals surviving beyond 3 weeks of virus inoculation 
demonstrated no signs of encephalitis and developed normally. Groups of five randomly 
chosen HSV-1-infected or mock-infected mice were euthanized at 1, 12 and 31 weeks after 
inoculation. TG were aseptically removed from euthanized animals, and tissues were 
processed for immunohistochemical staining for HSV-1 antigen and in situ hybridization for 
LAT expression to document acute or latent HSV-1 infection and to evaluate for 
histopathologic evidence of inflammation (Fig. 3–5). 
No HSV-1 protein expression was detected in the TG of mock-infected mice at any 
time point (Fig. 3A, C, and E). In five animals euthanized 1 week after HSV-1 inoculation, 
HSV-1 proteins were detected in all 10 TG by immunostaining (Fig. 3B), consistent with 
replication of HSV-1. HSV-1 proteins were detected in numerous cells that by morphological 
criteria were neurons and non-neuronal cells. In TG derived from animals euthanized at 12 
and 31 weeks after corneal HSV-1 inoculation, HSV-1 protein expression was not detected in 
the TG derived from four out of five mice tested (Fig. 3D, F). 
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Figure 3. HSV-1 protein expression in murine TG tissues following corneal inoculation of HSV-1 or sterile 
medium (mock-infection) as detected by immunohistochemistry. Brown staining indicates HSV-1 proteins. 
HSV-1 protein expression was not detected in TG derived from mock-infected mice at 1 (A), 12 (C) or 31 (E) 
weeks after mock inoculation. HSV-1 protein expression in a neuron in a TG derived from a mouse 1 week after 
corneal HSV-1 inoculation (B). HSV-1 protein expression was not detected in TG derived from mice 12 (D) or 
31 (F) weeks after corneal HSV-1 inoculation. Magnification = 400x. 
 
 
One TG section at each time point demonstrated very rare non-neuronal cells that 
stained for HSV-1 proteins (data not shown). Abundant LAT RNA expression was detected 
by in situ hybridization in TG tissues of HSV-1-infected mice euthanized at 12 and 31 weeks 
after virus inoculation (Fig. 4). 
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Figure 4. Detection of HSV-1 LAT in the TG of mice by in situ hybridization. Accumulation of dark grains 
indicates LAT accumulation. There was no evidence of LAT expression in TG derived from a mouse 31 weeks 
after corneal mock inoculation (A). Numerous LAT-positive cells in TG tissue derived from a mouse 31 weeks 
after corneal HSV-1 inoculation (B). Magnification = 200x. 
 
 
Sections of TG stained with hematoxylin and eosin at 1, 12, and 31 weeks after HSV-1 
inoculation revealed chronic inflammatory changes (Fig. 5B, D, and F). Inflammation was not 
detected in the TG of mock-infected animals (Fig. 5A, C, and E). These findings indicate that 
mice examined at 1 week after virus inoculation were productively infected with HSV-1, 
whereas those examined at 12 and 31 weeks after inoculation were latently infected with the 
virus. Marginal HSV-1 expression in one mouse each at 12 and 31 weeks after virus 
inoculation is consistent with rare focal HSV-1 reactivation. In addition, both acute and latent 
HSV-1 infection in the murine TG was associated with inflammation. 
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Figure 5. Inflammation in murine TG tissues following corneal inoculation of HSV-1. No evidence of 
inflammation in hematoxylin and eosin stained sections of TG derived from mice at 1 (A), 12 (C), or 31 (E) 
weeks after corneal mock inoculation. Chronic inflammation in hematoxylin and eosin stained sections of TG 
derived from mice at 1 (B), 12 (D), and 31 (F) weeks after corneal HSV-1 inoculation. Magnification = 100x 
 
 
4.1.2 Mean neuron diameter, mean neuronal nucleus diameter, and the number of neurons 
increase in the TG of mock-infected BALB/c mice 
 
Mean neuron diameter and mean neuronal nucleus diameter gradually increased in the 
TG of control mice between 1 and 31 weeks after mock infection (between 6 and 36 weeks of 
age) (Tab. 1). Specifically, mean neuron diameters at 6, 17, and 36 weeks of age were 22.74 ± 
5.2 µm (n=700), 22.98 ± 4.9 µm (n=700) and 25.16 ± 5.0 µm (n=900), respectively. Mean 
neuronal nucleus diameters at 6, 17, and 36 weeks of age were 9.15 ± 2.2 µm (n=700), 9.27 ± 
1.8 µm (n=700), and 10.33 ± 2.0 µm (n=900), respectively. Increases in mean neuron 
diameter and neuronal nucleus diameter did not differ statistically between 6 and 17 weeks 
(p=0.3782 and 0.2794, respectively), but were significantly different at 6 and 36 weeks and 17 
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and 36 weeks (p<0.0001). These findings are consistent with growth of TG neurons during the 
observation interval.  
Neuron density in the TG decreased while TG volume increased in mock-infected 
mice during the period of observation. The combination of these changes resulted in a gradual 
increase in the mean number of neurons per TG between 6 and 36 weeks of age (Tab. 1, Fig. 
6A, B, C). Neuron density was 5.64 ± 0.2 x 10
-5
 neurons per µm
3
 at 6 weeks of age (n=5) and 
decreased to 4.59 ± 0.2 x 10
-5
 neurons per µm
3 
by 17 weeks (n=5, p=0.000191). Neuron 
density was 4.51 ± 0.1 x 10
-5
 neurons per µm
3 
at 36 weeks of age (n=5), which was similar to 
that of 16 weeks (p=0.99) but significantly less than at 6 weeks of age (p=0.000082). Mean 
TG volume was 0.33 ± 0.03 mm
3
 at 6 weeks of age (n=5), 0.53 ± 0.04 mm
3 
at 17 weeks (n=5), 
and 0.89 ± 0.04 mm
3 
at 36 weeks of age (n=5) (Tab. 1, Fig. 6B). These increases were 
statistically significant (6 to 16 weeks: p=0.000006; 17 to 36 weeks: p=0.000005; 6 to 36 
weeks: p=0.0000001). The mean number of neurons per TG was 18600 ± 1000 (n=5), 24250 
± 1800 (n=5), and 40950 ± 3100 (n=5) at 6, 17, and 36 weeks of age, respectively (Tab. 1, 
Fig. 6C). These increases were statistically significant (6 to 16 weeks: p=0.00054; 17 to 36 
weeks: p=0.000013; 6 to 36 weeks: p=0.000001). Thus, TG volume and neuron number per 
TG increase, while neuron density decreases in the TG of mice between 6 and 36 weeks of 
age. 
 
 
Age 
(weeks) 
 
Inocu- 
lation 
HSV-1 
protein 
HSV-1 
LAT 
Inflam- 
mation 
Neuron 
diameter 
(µm ±SD) 
 
Neuron 
nucleus 
diameter 
(µm ± SD) 
 
Neurondensity 
(per µm
3
 ± SD ‡) 
 
TG 
volume 
(mm
3 
± SD) 
 
Neuron number/TG 
(thousand ± SD) 
 
6 Mock - - - 22.74 ± 5.2 9.15 ± 2.2 5.64 ± 0.2 0.33 ± 0.03 18.6 ± 1.0 
17 Mock - - - 22.98 ± 4.9 9.27 ±1.8 4.59 ± 0.2 0.53 ± 0.04 24.25 ± 1.8 
36 Mock - - - 25.16 ± 5.0 10.33 ± 2.0 4.51 ± 0.1 0.89 ± 0.04 40.95 ± 3.1 
6 HSV-1 + + + 23.94 ± 5.2 9.58 ± 2.0 5.15 ± 0.1 0.33 ± 0.03 17.0 ± 1.4 
17 HSV-1 -† + + 22.25 ± 4.6 9.07 ± 1.8 4.18 ± 0.2 0.53 ± 0.03 21.28 ± 2.2 
36 HSV-1 -† + + 23.55 ± 5.4 9.76 ± 2.0 3.91 ± 0.2 0.86 ± 0.04 33.62 ± 1.6 
 
Table 1. Expression of HSV-1 protein and LAT, inflammation and changes in neuron diameter, neuron 
nucleus diameter, neuron density, trigeminal ganglion (TG) volume and neuron number in the TG of 
BALB/c mice following corneal inoculation of either HSV-1 or sterile medium (mock-inoculation) at 5 
weeks of age.  
† 1 out of 10 TG studied demonstrated weak HSV-1 protein expression in a few cells. ‡ Results are multiplied by 
10
-5
. HSV-1 protein = herpes simplex virus-1 protein expression as detected by immunohistochemistry; HSV-1 
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LAT = herpes simplex virus-1 latency associated transcript expression as detected by in situ hybridization; SD = 
standard deviation; TG = trigeminal ganglion; N = total number of neurons. 
 
 
4.1.3 Productive HSV-1 infection in the TG of mice is associated with increased mean neuron 
diameter and neuronal nucleus diameter and decreased neuron density 
 
In the TG of mice euthanized 1 week after corneal HSV-1 inoculation, mean neuron 
diameter and mean neuronal nucleus diameter were greater than that detected in TG derived 
from mice 1 week after mock infection (Tab. 1). Specifically, mean neuron diameter 1 week 
after HSV-1 inoculation was 23.94 ± 5.2 µm (n = 1200) vs. 22.74 ± 5.2 µm (n = 700) in age-
matched mock-infected controls (Tab. 1, p = 0.0001), a 5.27% increase (Tab. 2). Mean 
neuronal nucleus diameter 1 week after HSV-1 inoculation was 9.58 ± 2.0 µm (n = 1200) vs. 
9.15 ± 2.2 µm (n = 700) detected in controls (Tab. 1, p = 0.0001), representing a 4.7% 
increase (Tab. 2). These changes in mean neuron diameter and neuronal nucleus diameter are 
consistent with the cytopathic effects associated with HSV-1 replication in a subset of the 
ganglionic neurons. Indeed, analysis of TG sections derived from mice 1 week following 
virus inoculation and immunostained for HSV-1 proteins indicated that mean neuron diameter 
and neuronal nucleus diameter were significantly greater in HSV-1 protein expressing neurons 
than in HSV-1 antigen–negative neurons (p < 0.001). Specifically, mean neuron diameter and 
neuronal nucleus diameter measurements were 31.10 ± 6.36 µm (n = 27) and 14.22 ± 2.32 µm 
(n = 12), respectively, in HSV-1 antigen–positive neurons, while mean neuron diameter and 
neuronal nucleus diameter were measured at 25.93 ± 4.32 µm (n = 50) and 11.66 ± 1.5 µm (n 
= 50), respectively, in HSV-1 antigen–negative neurons. 
Mean neuron density was 8.69% less (5.15 ± 0.1 x 10
-5
 neurons per µm
3
, n = 5) in TG 
derived from HSV-1-inoculated mice than in mock-infected controls (5.64 ± 0.2 x 10
-5
 
neurons per µm
3
, n = 5) 1 week after inoculation (Tab. 1 and 2, Fig. 6A, p = 0.002646). Mean 
TG volume was similar [0.33 ± 0.3 mm
3
 (n = 5) vs. 0.33 ± 0.3 mm
3
 (n = 5)] in HSV-1- and 
mock-infected mice at 1 week after inoculation (Tab. 1, Fig. 6B). The mean number of 
neurons per TG was 17 000 ± 1400 (n = 5) in virus-infected vs. 18 600 ± 1000 (n = 5) in 
mock-infected TG (Tab. 1, Fig. 6C), an 8.61% decrease (Tab. 2). This decreasing tendency in 
neuron number per TG did not reach statistical significance (p = 0.082395). Collectively, 
these findings are consistent with neuron destruction by productive HSV-1 infection in the 
TG. 
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Figure 6. Median and range of neuron density per TG (A), TG volume (B) and neuron number per TG (C) 
in mice euthanized 1, 12 and 31 weeks after corneal inoculation of HSV-1 or sterile medium (mock) at 6, 
17 and 36 weeks of age. TG number (n) was 5 for all time points and treatment groups. Rectangles represent 
25% to 75% quartiles. *p < 0.05; **p < 0.001; ***p < 0.0001. 
 
  
A B 
C 
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Age 6 weeks 17 weeks 36 weeks 
Neuron diameter (infected/control) +5.27% -3.17% -6.4% 
Neuron nucleus diameter 
(infected/control) 
+4.7% -2.15% -5.5% 
Neuron density (infected/control) -8.69% -8.94% -13.3% 
Neuron number per TG 
(infected/control) 
-8.61% -12.25% -17.9% 
 
Table 2. Percentage of change in mean neuron diameter, mean neuronal nucleus diameter, neuron density 
and mean neuron number per TG in HSV-1-infected mice relative to age-matched mock-infected control. 
 
 
4.1.4 Latent HSV-1 infection in the TG of mice is associated with decreased mean neuron 
diameter, neuronal nucleus diameter and neuron density and number 
 
In the TG of mice euthanized 12 weeks after corneal HSV-1 inoculation (at 17 weeks 
of age), mean neuron diameter, mean neuronal nucleus diameter, neuron density and mean 
neuron number per TG were all significantly less than those in age-matched mock-infected 
control mice (Tab. 1 and 2, Fig. 6A, C). Specifically, mean neuron diameter at 12 weeks after 
HSV-1 inoculation was 22.25 ± 4.6 µm (n=1000) vs. 22.98 ± 4.9 µm (n=700) detected in age-
matched mock-infected controls (Tab. 1, p=0.0023), a 3.17% decrease (Tab. 2). Mean 
neuronal nucleus diameter at 12 weeks after HSV-1 inoculation was 9.07 ± 1.8 µm (p=1000) 
vs. 9.27 ± 1.8 µm (p=700) in controls (Tab. 1, p=0.0249), a 2.15% reduction (Tab. 2). Neuron 
density was 8.94% less (4.18 ± 0.2 x 10
-5
 neurons per µm
3
, n=5) in TG derived from HSV-1-
infected mice in comparison with those from mock-infected mice (4.59 ± 0.2 x 10
-5
 neurons 
per µm
3
, n=5) at 12 weeks after inoculation (Tab. 1, Fig. 6A, p=0.00458). Mean TG volume 
did not differ significantly (0.53 ± 0.03 vs. 0.53 ± 0.04 mm
3
, n=5 for each) in HSV-1- and 
mock-infected mice at 12 weeks after inoculation (Tab. 1, Fig. 6B). However, the mean 
number of neurons per TG was significantly less in HSV-1-infected mice than in mock-
infected mice at 12 weeks after inoculation (Tab. 1, Fig. 6C). Specifically, the total number of 
neurons was 21280 ± 2200 (n=5) in virus-infected vs. 24250 ± 1800 (n=5) in mock-infected 
TG (Tab. 1, Fig. 6C; p=0.04718), a 12.25% decrease (Tab. 2). Thus, neuron size and number 
are decreased in the TG of mice 12 weeks after HSV-1 corneal inoculation. 
In the TG of mice euthanized 31 weeks after corneal HSV-1 inoculation (at 36 weeks 
of age), mean neuron diameter, mean neuronal nucleus diameter, neuron density, and mean 
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neuron number per TG were all significantly less than those detected in age-matched mock-
infected control mice (Tab. 1, Figs. 6A, B). Specifically, mean neuron diameter at 31 weeks 
after HSV-1 inoculation was 23.55 ± 5.4 µm (n=1000) vs. 25.16 ± 5.0 µm (n=900) in age-
matched mock-infected controls (Tab. 1, p=0.0001), a 6.4% decrease (Tab. 2). Mean neuronal 
nucleus diameter at 31 weeks after HSV-1 inoculation was 9.76 ± 2.0 µm (n=1000) vs. 10.33 
± 2.0 µm(n=900) in controls (Tab. 1, p=0.0001), a 5.5% reduction (Tab. 2). Neuron density 
was 13.3% less (3.91 ± 0.2 x 10
-5
 neurons per µm
3
, n=5) in TG derived from HSV-1-infected 
mice in comparison with those from mock-infected mice (4.51 ± 0.1 x 10
-5
 neurons per µm
3
, 
n=5) at 31 weeks after inoculation (Tab. 1, Fig. 6A, p=0.000054). Mean TG volume did not 
differ significantly (0.86 ± 0.04, n=5 vs. 0.89 ± 0.04 mm
3
, n=5) in HSV-1- and mock-infected 
mice at 31 weeks after inoculation (Tab. 1, Fig. 6B). However, like the TG from mice at 12 
weeks after HSV-1 inoculation, the number of neurons per TG was significantly less in HSV-
1-infected mice than in mock-infected mice at 31 week after inoculation (Tab. 1, Fig. 6C). 
Specifically, the total number of neurons was 33.620 ± 1600 (n=5) in virus-infected vs. 40950 
± 3100 (n=5) in mock-infected TG (Tab. 1, p=0.0016), a 17.9% relative decrease (Tab. 1, Fig. 
6C). 
Deficits in mean neuron diameter, neuron nucleus diameter, neuron density, and 
neuron number per TG relative to age-matched mock-infected controls were all more 
substantial at 31 weeks that at 12 weeks after corneal virus inoculation (Tab. 2). As only latent 
HSV-1 infection was detected in TG neurons at 12 and 31 weeks after corneal virus 
inoculation, the progressive deficits in neuron size, density, and number between these times 
are consistent with chronic progressive neural injury during latent HSV-1 infection. 
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4.2 Investigation of HSV-1 latency in tumor cells and the effect of extracellular matrix 
concerning latently infected  tumor cells 
 
4.2.1 OCM1 and C918 uveal melanoma cells form several morphologically distinct cell 
populations under 3D culture conditions 
 
To define in detail the growth pattern of uveal melanoma cells in 2D and 3D cultures, 
OCM1 and C918 cells were grown either in the presence or absence of laminin-rich ECM 
(Matrigel). In the absence of Matrigel (2D cultures), both OCM1 and C918 grew in 
monolayers (Fig. 7A, B). In the presence of Matrigel, both cell lines developed 3D structures 
(Fig. 7C–H; Fig. 8A–D; Fig. 9A–D). When OCM1 cells were placed on the Matrigel surface, 
cells first formed aggregates that were loosely attached to the Matrigel surface (Fig. 7C; Fig. 
8A). As the cell aggregates were growing further, their attachment to the Matrigel surface 
became wider and firmer and single tumor cells began to invade the Matrigel matrix (Fig. 8A, 
B). During further growth, individual tumor cells invaded the matrix deeply and some of these 
cells formed multicellular spheroids showing a smooth surface and consisting of cells tightly 
attached to each other (Fig. 7E; Fig. 8C). Tumor cell aggregates on the Matrigel surface also 
showed similar spheroid formation at their bottom portion that completely immersed in the 
Matrigel matrix (Fig. 8B, C). Many of the tumor cell spheroids were stable for days to weeks, 
whereas others showed outgrowth of individual cells into the matrix. Cells invading the 
matrix (Fig. 7G) eventually reached the bottom of the tissue culture plate and grew under the 
matrix in monolayers (Fig. 8D). The growth of OCM1 cells within the Matrigel matrix did not 
cause massive destruction of the matrix until the end of the 4-week observation period.  
When C918 cells were placed on the Matrigel surface, the cells started to grow on the 
matrix surface in a single layer and formed circular vasculogenic mimicry patterns that 
surrounded round matrix surfaces free of tumor cells (Fig. 7D; Fig. 9A). Next, individual 
tumor cells started to grow into the Matrigel at the line defined by the vasculogenic mimicry 
patterns (Fig. 7F; Fig. 9B). Cells invading the matrix migrated to the bottom of the culture 
plate and formed monolayers there (Fig. 7H; Fig. 9C, D). Interestingly, the formation of 
monolayers at the bottom of the well was restricted to areas under the Matrigel surfaces not 
colonized by cells but were surrounded by vasculogenic mimicry patterns (Fig. 9C). Next, 
individual tumor cells invaded the matrix underlying cell monolayers on the Matrigel surface 
(Fig. 9D). Tumor cell growth and matrix invasion eventually caused a loss of Matrigel in 
areas surrounded by vasculogenic mimicry patterns (Fig. 9D).  
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Figure 7. Morphology of OCM1 and C918 uveal melanoma cells grown in either 2D or 3D cultures. OCM1 
cells grown in 2D monolayers for 5 days (A). Five-day-old 3D OCM1 culture. Arrow indicates surface aggregate 
of cells (C). Same 3D OCM1 culture with focus deeper on multicellular spheroid (arrow) within Matrigel (E). 
Same 3D OCM1 culture with focus even deeper on individual tumor cells (arrows) invading Matrigel (G). C918 
cells grown in 2D monolayers for 5 days (B). Three-day-old 3D C918 culture with focus on Matrigel surface. 
Arrow indicates vasculogenic mimicry forming cells and asterix marks tumor cells growing in monolayer on 
Matrigel surface (D). Same 3D C918 culture with focus on tumor cells (arrow) invading the Matrigel matrix (F). 
Six-day-old 3D C918 culture with focus on tumor cells growing in monolayer under the Matrigel matrix (H). 
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These observations confirm and extend earlier observations related to the morphology 
of uveal melanoma cultures [64] and indicate that OCM1 and C918 uvealmelanoma cells 
form several morphologically distinct cell populations under 3D culture conditions. 
 
 
 
Figure 8. Schematic illustration of the mor-
phology of 2-day-old (A), 3-day-old (B), 4-day-
old (C), and 5-day-old (D) 3D OCM1 uveal 
melanoma cultures. 
 
Figure 9. Schematic illustration of the mor-
phology of 2-day-old (A), 3-day-old (B), 4-day-old 
(C), and 5-day-old (D) 3D C918 uveal melanoma 
cultures.  
 
4.2.2 Rapid destruction of 2D and a delayed and incomplete destruction of 3D uveal melanoma 
cultures by wt HSV-1 and HSV-1 K26GFP 
 
2D and 3D cultures of OCM1 and C918 cells were inoculated with wt HSV-1 strain KOS 
or HSV-1 strain K26GFP by placing virus solutions on the surface of the cultures. HSV-1 
K26GFP exhibits fluorescence on replication [63]. Cultures were followed for evidence of 
cytopathic effects and virus replication (GFP expression/fluorescence) by an inverted 
fluorescence microscope. 
We found that 2D cultures were completely destroyed by both HSV-1 strains within a few 
days (Tab. 3) with no evidence of surviving cells by Trypan blue staining. In contrast, virus 
inoculated 3D cultures showed delayed and incomplete destruction (Tab. 3). Importantly, a 
portion of both OCM1 and C918 cells seemed to survive HSV-1 KOS and HSV-1 K26GFP 
infection in 3D cultures for up to 4 weeks. Cell populations with increased resistance included 
C918 cells that formed vasculogenic mimicry patterns on the Matrigel surface, OCM1 cells that 
formed multicellular spheroids within the Matrigel matrix, and both C918 and OCM1 cells that 
invaded Matrigel individually. 
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Cell line Culture condition HSV-1 strain Day of 95% destruction 
OCM1 2D 
3D 
2D 
3D 
KOS 
KOS 
K26GFP 
K26GFP 
4 
8 
4 
8 
C918 2D 
3D 
2D 
3D 
KOS 
KOS 
K26GFP 
K26GFP 
5 
9 
5 
9 
 
Table 3. Elapsed time from inoculation of HSV-1 KOS or HSV-1 K26GFP (at M.O.I.=0.5 PFU per cell) to 
at least 95% destruction of 2D and 3D OCM1 and C918 uveal melanoma cultures. 
 
 
In K26GFP inoculated 2D OCM1 and C918 cultures, 20–50% of tumor cells showed 
GFP expression by 1 day post infection (p.i.), and after 3 days p.i., it was very difficult to find 
any cells without fluorescence consistent with the complete viral replication-mediated 
destruction of these cultures by 4–5 days (Fig. 10A, B; Fig. 12A, B). In contrast, 3D cultures 
of both OCM1 and C918 showed a significant number of GFP-negative cells throughout the 
4-week observation period (Fig. 10C–H; Fig. 11A–F; Fig. 12C–H; Fig. 13A–F). 
In 3D cultures of OCM1, cells forming aggregates on the Matrigel surface showed 
widespread fluorescence (virus replication) by 1 day p.i., and after 4 days p.i., it was very 
difficult to find any cells without fluorescence in these structures consistent with the complete 
virus-mediated destruction of these surface cell aggregates by K26GFP by 8 days p.i. (Fig. 
10C, D). Individual OCM1 cells growing into the Matrigel matrix showed variable 
fluorescence and some apparently viable and GFP-negative cells were consistently present 
during the 4-week observation period. Cells forming multicellular spheroids inside the matrix 
and cells forming spheroids at the bottom, matrix immersed portion of surface aggregates 
showed marked resistance to HSV-1 replication (Fig. 10C–H; Fig. 11A, B). Although 
occasional spheroids showed widespread fluorescence by 4 days p.i., others contained only a 
few GFP-positive cells and many remained completely devoid of GFP expression for days to 
weeks. GFP-negative spheroids contained viable cells as radial outgrowth of individual cells 
into the Matrigel matrix was observed from many of these structures as the cultures were 
aging (Fig. 11A, C, E). Interestingly, this outgrowth was often associated with the appearance 
of fluorescence in outgrowing cells and in cells within the spheroids (Fig. 11D, F), whereas in 
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other cases, both spheroids and outgrowing cells remained GFP negative (Fig. 11B). Cells 
growing under the matrix in monolayers were susceptible to HSV-1 and showed widespread 
fluorescence.  
 
 
 
 
Figure 10: Morphology and GFP expression in HSV-1 K26GFP inoculated OCM1 uveal melanoma 2D 
and 3D cultures. 2D OCM1 culture 1 day after virus inoculation; morphology (A) and GFP expression (B). 3D 
OCM1 cultures 1 day after virus inoculation; morphology (C) and GFP expression (D). Arrows in panel (C) 
indicate tumor cell aggregates on the Matrigel surface that are GFP positive in panel D and arrowhead in panel C 
indicates a multicellular spheroid within the Matrigel matrix that is GFP negative in panel D. 3D OCM1 cultures 
3 days after virus inoculation; morphology (E) and GFP expression (F). Arrowhead in panel E indicates a 
multicellular spheroid within the Matrigel matrix that is GFP negative in panel F. 3D OCM1 cultures 12 days 
after virus inoculation; morphology (G) and GFP expression (H). Arrowhead in panel G indicates a multicellular 
spheroid within the Matrigel matrix showing outgrowth of individual tumor cells at the periphery that is GFP 
negative in panel H. 
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Figure 11: Morphology and GFP expression in HSV-1 K26GFP inoculated 3D OCM1 uveal melanoma 
cultures 12 days after virus inoculation. Arrowhead in panel (A) indicates a multicellular spheroid within the 
Matrigel matrix that shows outgrowth of individual tumor cells at its periphery that are GFP negative in panel 
(B). Arrowhead in panel (C) indicates a multicellular spheroid within the Matrigel matrix showing outgrowth of 
individual tumor cells. Some of the outgrowing tumor cells show GFP expression in panel (D). Arrowhead in 
panel (E) indicates a multicellular spheroid within the Matrigel matrix with outgrowth of individual tumor cells 
at the periphery with cells within the core of the spheroid showing GFP expression in panel (F). 
 
 
In 3D cultures of C918 cells, cells growing on the matrix surface in a single layer 
showed widespread fluorescence (virus replication) as early as 1 day p.i. consistent with the 
complete destruction of this cell population by K26GFP by 9 days p.i. (Fig. 12C, D). In 
contrast, cells forming vasculogenic mimicry patterns on the Matrigel surface showed 
increased resistance to HSV-1 (Fig. 12E, F) and GFP-negative cells could be observed in 
these structures throughout the 4-week observation period. Similarly, cells invading the 
matrix individually showed increased resistance to HSV-1 and this cell population also 
included many GFP-negative cells throughout the 4-week observation period (Fig. 12G–H; 
13A-F). Tumor cells growing in monolayers under the Matrigel showed widespread 
fluorescence and susceptibility to HSV-1 (Figure 12E, F).  
37 
These observations clearly identify certain uveal melanoma populations with increased 
resistance against HSV-1 in the 3D environment. Consequent experiments were designed to 
identify the mechanism(s) responsible for the observed resistance of tumor cells against HSV-
1 in 3D cultures. 
 
 
 
 
Figure 12. Morphology and GFP expression in HSV-1 K26GFP inoculated C918 uveal melanoma cells 
grown in 2D and 3D cultures. 2D C918 monolayer culture 3 days after virus inoculation; morphology (A) and 
GFP expression (B). 3D C918 culture 3 days after virus inoculation; morphology (C) and GFP expression (D). 
Arrow in panel (C) indicates tumor cells growing in monolayer on the Matrigel surface that express GFP in panel 
(D). 3D C918 culture 3 days after virus inoculation; morphology (E) and GFP expression (F). Arrow in panel (E) 
indicates tumor cells forming vasculogenic mimicry pattern on the Matrigel surface that only partially expresses 
GFP in panel (F). 3D C918 culture 3 days after virus inoculation; morphology (G) and GFP expression (H). 
Arrow in panel (G) indicates a tumor cell invading Matrigel that does not express GFP in panel (H). Arrowhead 
in panel (G) indicates a tumor cell invading Matrigel that expresses GFP in panel (H). 
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Figure 13. Morphology (A, C, E) and GFP expression (B, D, F) of cells invading the Matrigel matrix in 
HSV-1 K26GFP inoculated 3D C918 uveal melanoma cultures 12 days after virus inoculation. Note the 
lack of GFP expression in panels (B, D) and the variable expression of GFP by tumor cells in panel (F). 
 
 
4.2.3 Matrigel impairs HSV-1 spread 
 
To determine whether inhibition of HSV-1 spread through Matrigel was a mechanism 
responsible for the absence of virus replication (GFP expression) in some tumor cells in 3D 
cultures, monolayers of OCM1 and C918 cells were covered with an approximately 1mm 
thick layer of Matrigel and then HSV-1 K26GFP was placed on the Matrigel surface. As 
controls, monolayers of OCM1 and C918 cells without a Matrigel cover were also inoculated 
with the same amount of virus. Virus inoculated uveal monolayers with no Matrigel cover 
showed widespread GFP expression by 18–24 h p.i. and were completely destroyed within a 
few days. In contrast, cells covered with Matrigel and inoculated with HSV-1 K26GFP 
showed continued viability and growth during a 2-week observation period with no evidence 
of GFP expression. These findings indicate that Matrigel inhibits HSV-1 spread. 
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4.2.4 ECM mediates inhibition of HSV-1 replication after virus entry into tumor cells 
 
To determine whether inhibition of viral replication after virus entry into tumor cells is 
a mechanism responsible for the absence of virus replication (GFP expression) in some tumor 
cells in 3D cultures, uveal melanoma cells were first inoculated with HSV-1 K26GFP under 
2D conditions (allowing for unimpeded entry of virus into cells) and were then cultured under 
either 2D or 3D conditions.  
After the plating of earlier mock-infected OCM1 and C918 cells on tissue culture 
dishes, tumor cells established monolayers (2D cultures) that showed normal growth and no 
evidence of GFP expression. Growing of earlier mock-infected OCM1 and C918 cells under 
3D conditions in Matrigel was initially associated with single cells suspended in matrix. After 
the first day, growth of OCM1 cells was associated with the development of tumor cell 
spheroids, many of which later showed outgrowth of individual cells into the matrix. Growth 
of mock-infected C918 cells was associated with the establishment of extensive network of 
tumor cells invading the matrix. No GFP expression was detected in the mock-infected 3D 
cultures of OCM1 and C918 cells. 
After the plating of earlier HSV-1 K26GFP inoculated OCM1 and C918 cells on tissue 
culture dishes, tumor cells established monolayers (2D cultures) that were completely 
destroyed by virus replication within a few days. At 18 h p.i., 29.53 ± 15.01% of OCM1 cells 
and 40.33 ± 15.17% of C918 cells showed fluorescence (evidence of HSV-1 replication) (Tab. 
4). Nearly all OCM1 cells were GFP positive by 72 h and nearly all C918 cells were GFP 
positive by 96 h. These findings are consistent with replication of input virus in infected cells 
at 18 h p.i. and virus spread to all cells in the following days. 
Culturing of earlier HSV-1 K26GFP inoculated OCM1 and C918 cells in 3D was 
initially associated with single cells suspended in matrix. More than half of the cells showed 
morphologic changes during the first day of the establishment of the 3D cultures including 
rounding and a minority of cells showed morphological features of apoptosis. At 18 h p.i., the 
numbers of OCM1 and C918 cells in the virus-infected 3D cultures were 12.5 and 8.5% lower 
than those in their mock-infected 3D counterparts. At 18 h p.i., 2.80 ± 2.75% of OCM1 cells 
and 2.22 ± 3.05% of C918 cells showed fluorescence (Tab. 4) in the HSV-1-infected 3D 
cultures. The number of GFP-expressing cells did not increase the following days. Thus, at 18 
h p.i., a significantly smaller percentage of cells showed evidence of virus replication in 3D 
cultures than what was expected on the basis of the amount of input virus. These observations 
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indicate that the ECM can mediate the inhibition of HSV-1 replication after virus entry into 
tumor cells.  
 
 
Cell line Inoculation in 2D Consequent culture Percent of cells 
GFP +
 a
 
OCM1 Mock 
HSV-1 K26GFP 
Mock 
HSV-1 K26GFP 
2D 
2D 
3D 
3D 
0 
29.53 ± 15.01 
0 
2.8 ± 2.75 
C918 Mock 
HSV-1 K26GFP 
Mock 
HSV-1 K26GFP 
2D 
2D 
3D 
3D 
0 
40.33 ± 15.17 
0 
2.22 ± 3.05 
 
Table 4. GFP expression in OCM1 and C918 uveal melanoma cells inoculated with 0.5 PFU per cell of 
HSV-1 K26GFP or mock infected with PBS under 2D conditions for 1 h and then cultured for 17 h either 
under 2D or 3D conditions. 
a
Percentage of GFP-expressing cells was determined by counting the number of 
GFP-expressing and GFP-negative cells in 16 high power microscopic fields for each studied type of treatment. 
 
 
In HSV-1-infected 3D cultures, the majority of cells remained GFP negative 
throughout a 4-week observation period (data not shown). Interestingly, the outgrowth of 
individual OCM1 cells into the Matrigel matrix from spheroids that have been GFP negative 
for days to weeks was occasionally associated with the appearance of GFP expression in 
outgrowing cells and in cells within the spheroids similarly to the process shown in Fig. 11C-
F. As Matrigel does not allow HSV-1 spread, these observations suggest that HSV-1 
established a quiescent infection in some tumor cells within multicellular spheroids and that 
this quiescent infection could revert to productive viral infection when the tumor growth 
pattern changed. 
  
41 
5. DISCUSSION 
 
A general biological characteristic of herpes viruses is their ability to sustain lifelong 
infection of the host despite an operable immune response. The complex mechanism behind 
this process is called latency and can be defined as an infection in which the viral genome 
exists in a non-replicating form in an infected cell from which the virus can periodically 
reactivate. Occasional re-activation and shedding of the virus then allows the infection of new 
hosts and maintains high levels of viral infection, and seropositivity, within the population 
[65]. Recurrent lesions develop during the life of an infected individual, generally at epithelial 
sites such as lips (herpes labialis), oral cavity (herpetic stomatitis), the eye (herpetic keratitis), 
orofacial complex (herpes facialis) and skin. Additionally, epidemiological data suggest that 
HSV-1 is one of the environmental risk factors for Alzheimer’s disease which disease 
characterized by progressive neuron loss, brain atrophy, and cognitive impairment [66, 67]. 
Furthermore many properties – including latency – instates HSV-1 especially appropriate for 
using it as a vector to treat inherited genetic diseases affecting the nervous system, such as 
ataxias, chronical diseases of the central nervous system, such as Parkinson´s disease or 
mediate selective oncolysis of malignant brain tumors (―virus therapy‖) [68]. 
In our first model system we used quantitative morphometric analyses to test whether 
latent HSV-1 infection affects mean neuron diameter, neuronal nucleus diameter, neuron 
density, and neuron number in the TG of mice. For these studies, we used TG tissues obtained 
from BALB/c mice 1, 12, and 31 weeks after corneal inoculation of HSV-1 at 5 weeks of age. 
These tissues were previously demonstrated to harbor productive HSV-1 infection at 1 week 
and latent HSV-1 infection at 12 and 31 weeks after virus inoculation (57). These results 
provide strong evidence that latent HSV-1 infection is associated with chronic progressive 
deficits in mean neuron diameter, neuronal nucleus diameter, neuron density, and neuron 
number in the murine TG. This work provides a link between HSV latency and progressive 
neural damage and establishes an experimental platform to explore mechanisms of HSV 
induced chronic neurological disease. We show here using careful morphometric analyses that 
in healthy adult mice, mean neuron diameter, mean neuron nucleus diameter, TG volume, and 
mean number of neurons per TG gradually increase between 6 and 37 weeks of age. The 
detection of increasing neuron diameter, neuronal nucleus diameter, and TG volume is not 
surprising and consistent with normal growth of these mice. Our findings of increasing neuron 
numbers in the TG of mock-infected mice are similar to those made in several reports of 
gradually increasing numbers of mature neurons in the sensory ganglia of healthy adult rats 
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[15, 16, 69-73]. In rats, both ongoing neurogenesis and maturation of undifferentiated or 
partially differentiated post-mitotic cells have been proposed as possible mechanisms for the 
observed increase in the number of mature neurons in adult animals [15, 16, 69-74]. A similar 
situation may be operant in mice.  
Numerous previous studies indicate that corneal inoculation of immunocompetent 
mice with HSV-1 is followed by virus replication in the TG for about two weeks, which in 
turn is followed by the establishment of life-long HSV-1 latency in the TG [47, 75]. 
Consistent with these reports and our previous analyses of the TG tissues used in this study 
[76], we detected productive HSV-1 infection in the TG at 1 week after virus inoculation and 
evidence of latent HSV-1 infection in the TG at 12 and 31 weeks after virus inoculation. In 
the TG of mice euthanized 1 week after corneal HSV-1 inoculation, mean neuron diameter 
and mean neuronal nucleus diameter increased, while neuron density and mean neuron 
number per TG decreased relative to age-matched mock-infected controls. These findings are 
not surprising as these ganglia harbor productive HSV-1 infection, and HSV-1 replication is 
associated with cytopathic effects that include cellular swelling and nuclear enlargement [77, 
78]. Furthermore, neuronal death in the TG of mice during the first few weeks of infection is 
well documented [75, 77, 79], which would account for the decrease in neuron number.  
The key finding of our study is that in the TG of mice 12 and 31 weeks after HSV-1 
inoculation (at 17 and 36 weeks of age), mean neuron diameter, neuronal nucleus diameter, 
neuron density, and mean neuron number per TG were significantly less than those in age 
matched mock-infected control TG. Interestingly, the deficits in neuron diameter, neuronal 
nucleus diameter, neuron density, and neuron number in latently infected TG were more 
substantial at 36 weeks than at 17 weeks of age. It is possible that diminished neuron size and 
number at 12 weeks after corneal virus inoculation is attributable to neuron destruction and 
delayed neuron growth caused by productive HSV-1 infection during the first weeks of 
infection. However, as only latent HSV-1 infection was detected in TG neurons at 12 and 31 
weeks after corneal virus inoculation, the progressive reductions in neuron size and number 
between these intervals are unlikely to occur as a consequence of virus replication during the 
first few weeks of infection.  
Mean neuron diameter, mean neuronal nucleus diameter, and mean neuron number per 
TG increased in absolute numbers between 17 and 36 weeks in latently infected mice. 
However, these increases were substantially less than those in mock-infected controls. 
Furthermore, the increases detected were less than expected for resumption of normal TG 
growth at these times. Resumption of normal TG growth would be expected to be associated 
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with stable or decreasing deficits in neuron size, density, and number in latently infected TG 
between 12 and 31 weeks after virus inoculation (between 16 and 36 weeks of age) relative to 
age-matched controls. However, these relative deficits all increased during latency. These 
findings indicate that latent HSV-1 infection is associated with chronic progressive deficits in 
neuron size, density, and number in the nervous system of an immunocompetent host.  
Mechanisms by which latent HSV-1 infection leads to chronic progressive alterations 
in neuron size, density, and number in the nervous system are not clear from our study. As 
spontaneous HSV-1 reactivation occurs in latently infected mice [47, 79], albeit rarely, it is 
possible that reactivation events contribute to changes in neuronal size and number. Detection 
of extremely rare HSV-1 protein-expressing cells in a minority of TG at 12 and 31 weeks after 
HSV-1 inoculation is consistent with virus reactivation. However, potential causes of 
progressive neuronal injury are not restricted to HSV-1 reactivation events, as latent infection 
and the associated persistent inflammatory response also can cause neuronal dysfunction and 
tissue injury [58, 59, 76, 80]. Latent HSV-1 infection in the murine TG is associated with low-
level expression of replication-cycle HSV-1 genes in the absence of infectious virus 
production [55]. Marginal HSV-1 protein expression associated with these incomplete 
reactivation attempts may induce neuronal injury. Persistent inflammation during HSV-1 
latency in the murine TG also may cause neuronal injury, possibly mediated by cytokines and 
oxidative stress [58, 59, 76]. Indeed, the extent of neuronal injury during latent infection in 
our current study seemed to correlate with the extent of inflammation in the TG. These viral 
and inflammatory processes may injure mature neurons or interfere with ongoing 
neurogenesis and neuronal maturation in the TG. 
While mice surviving the acute phase of experimental HSV infection do not show 
signs and symptoms of encephalitis, numerous studies documented chronic behavioral and 
neurological deficits and chronic pain in these animals [53, 54, 56, 57, 81-83]. In the current 
study, mice were observed daily for signs and symptoms of encephalitis, but detailed 
neurological and behavioral studies were not performed. Future experiments will need to 
determine whether HSV-1 latent infection-associated progressive pathologic changes 
documented here cause progressive neurological or behavioral deficits in mice. These studies 
will provide an excellent experimental platform to dissect mechanisms of HSV-induced 
chronic neurological disease. A role for genetic susceptibility of latent HSV-induced chronic 
neuronal injury should be a focus of future studies using this experimental system as genetic 
susceptibility has been repeatedly proposed to be important for the pathogenesis of HSV-
induced chronic neurological disease in humans [21, 84-90]. These studies may lead to major 
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new insights into mechanisms by which latent viral infections contribute to the pathogenesis 
of chronic neurological and neuropsychiatric diseases and foster development of virus-
specific intervention strategies. 
In our second model system we used 2D and 3D cultures of uveal melanoma cells and 
were designed to find answers to the following questions related to HSV-1 oncolytic therapy: 
(i) Can 3D tumor cell cultures be used to identify morphologically distinct tumor cell 
populations that have increased resistance to HSV-1? (ii) Can 3D tumor cell cultures be used 
to learn about mechanisms of ECM mediated tumor cell resistance to HSV-1 oncolytic 
therapy?  
We show for the first time that 3D tumor cell cultures can be used to identify 
morphologically distinct tumor cell populations with increased resistance to HSV-1. 
Specifically, we show that tumor cells forming vasculogenic mimicry patterns and 
multicellular spheroids and cells that invade the ECM individually have increased resistance 
to HSV-1. Furthermore, we show that mechanisms of tumor resistance against HSV-1 in the 
3D environment include impaired virus spread in the ECM and ECM-mediated inhibition of 
viral replication after viral entry into tumor cells. Observations reported here also suggest that 
HSV-1 can establish quiescent infection in some tumor cells present in multicellular spheroids 
and that this can revert to productive viral infection on outgrowth of individual tumor cells 
into the Matrigel matrix.  
It is well established that 3D tumor cell cultures are useful for preclinical evaluation of 
the cytotoxic effect of anticancer agents, and multiple cell types within individual tumors have 
differential sensitivities to drugs and radiation both in vivo and in 3D cultures [46, 48, 49, 91]. 
However, so far very few studies have used 3D tumor cell cultures in the context of viral 
oncolytic therapy. These studies have indicated that tumor cells grown in 3D cultures are also 
more resistant to viral, including HSV-1 and adenovirus-mediated oncolytic therapy, than 
cells grown in 2D culture [51, 52]. Observations reported here confirm and extend the finding 
of these studies and identify morphologically distinct tumor cell populations present in 3D 
cultures that have increased resistance to viral oncolytic therapy. These observations are likely 
of clinical relevance as, for instance, vasculogenic mimicry patterns are present in a wide 
variety of malignancies and their detection in several tumor types is associated with adverse 
outcome [92, 93].  
Factors limiting the effectiveness of HSV-1 oncolytic therapy remain poorly 
understood in part because related studies have been limited to expensive and time-consuming 
experimental animal models. Theoretical considerations and experimental observations made 
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thus far indicate that mechanisms of tumor resistance to HSV-1 therapy include ECM-
mediated impairment of intratumoral virus spread, impaired viral entry into tumor cells 
because of decreased expression of HSV-1 entry receptors, inhibition of viral replication after 
viral entry into tumor cells, and virus clearance by the host immune system [32-34, 38, 39, 41, 
94, 95]. In this study, we found that at least two of these potential mechanisms of virus 
resistance — impaired virus spread in the ECM and inhibition of viral replication after viral 
entry into tumor cells — are also relevant to 3D tumor cell cultures. 
HSV-1 oncolysis can be improved by degradation of fibrillar collagen in tumors 
indicating that the ECM has an important function in determining treatment efficacy [94]. 
This study indicates that laminin-rich ECM, Matrigel inhibits HSV-1 spread. These findings 
are consistent with the earlier reported inhibition of HSV-1 spread by epithelial basement 
membrane in vivo and by Matrigel in vitro [96]. It is important to note that HSV-1 could 
clearly infect and replicate in some uveal melanoma cells that have invaded the Matrigel 
matrix in this study. These observations indicate that HSV-1 can spread through Matrigel if 
tumor cells infiltrating the ECM are present. Whether HSV-1 can spread from cell to cell 
within the Matrigel matrix through intercellular contacts or through spaces in Matrigel created 
by growing tumor cells remains unclear at this point. 
This study also indicates that inhibition of viral replication at a stage beyond viral 
entry is an important mechanism by which the ECM can modulate viral replication in tumors. 
It is well known that adhesion of cancer cells to the ECM mediates drug and radiation 
resistance [46, 97, 98]. The connection of tumor cells to ECM proteins such as collagen and 
laminin through cell adhesion molecules, in particular integrin receptors, is associated with 
tumor cell survival and drug resistance through the activation of a variety of signaling 
pathways. It is unclear at this point to what extent, if any, mechanisms of drug and radiation 
resistance in 3D tumor cell cultures are overlapping with mechanisms of virus resistance. It is 
possible that ECM-mediated signaling affects the expression of cellular transcription factors 
that can regulate the expression of viral genes in a manner that is not favorable for the 
progression of the viral replication cycle after HSV-1 entry.  
Interestingly, observations made in this study suggest that HSV-1 establishes quiescent 
infection in some tumor cells in 3D cultures. When OCM1 and C918 cells were inoculated 
with HSV-1 under 2D conditions and were then cultured within Matrigel, only a small 
minority of tumor cells that have taken up HSV-1 showed evidence of virus replication (GFP 
expression). As discussed earlier, these findings indicated that the viral replication cycle was 
inhibited at a post-entry step in the majority of infected tumor cells. Consequent growth of 
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virus inoculated OCM1 cells in 3D cultures was associated with the establishment of 
multicellular tumor cell spheroids. Many OCM1 cells forming multicellular spheroids 
remained GFP negative throughout a 4-week observation period. However, the outgrowth of 
individual OCM1 cells into the Matrigel matrix from spheroids that have been GFP negative 
for days to weeks was often associated with the appearance of GFP expression in outgrowing 
cells and in cells within the spheroids. As Matrigel inhibits virus spread, reappearance of GFP 
expression in multicellular spheroids was very suggestive of virus reactivation from 
quiescence in earlier HSV-1 inoculated cells. It is well known that HSV-1 can establish 
quiescent infection in cultured non-neuronal cells if the progression of the viral replication 
cycle is blocked shortly after virus entry [75, 99]. However, establishment of quiescent 
infection in tumor cells induced by the ECM environment and reactivation of viral replication 
on changing tumor growth pattern have not yet been reported. It will be of practical 
significance to determine whether similar processes also occur in vivo during HSV-1 
oncolytic therapy. Our observations reported here provide novel information about virus 
resistance of distinct tumor cell subpopulations in 3D tumor cell cultures and about 
mechanisms of ECM-mediated virus resistance of tumor cells. It is clear that additional 
studies will be required to fully understand the mechanisms by which the ECM mediates 
increased HSV-1 resistance of tumor cells in 3D cultures and to assess the clinical relevance 
of information collected in these cultures. However, our observations suggest that the 
experimental platform provided by 3D tumor cultures will be invaluable for studies aimed at 
the improvement and preclinical evaluation of viral oncolytic agents similarly to its usefulness 
in the case of chemotherapeutic agents and radiation therapy.  
In summary, HSV-1 is an important human pathogen responsible for significant 
morbidity and mortality. To better understand the difficult and compound pathways 
cooperating with the pathogenesis of this virus the use of tissue and cell cultures and animal 
models are important, but thus far many issues regarding both pathogenesis and effective 
therapy are unclear. Intensive research concerning HSV-1 vectors is ongoing which can be 
used to express potential therapeutic genes or accomplish effective oncolysis of malignant 
tumors. It is clear from this discussion that there are plenty of mentioned topics requiring 
further exploration with focus on latency to broaden our current knowledge and thereby 
providing an improved patient care. 
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6. SUMMARY 
 
In our work, we investigated two aspects of HSV-1 latency using in vivo and in vitro 
model systems. In the first part of our work, we examined some pathologic consequences of 
latent HSV-1 infection in mice and in the second part of our work we examined melanoma 
resistance to HSV-1-mediated oncolysis using two uveal melanoma cell lines. 
Primary infection with HSV-1 is rapidly controlled by immunocompetent individuals 
but result in the establishment of viral latency in neurons primarily in peripheral sensory 
ganglia. Latent HSV-1 infection of the trigeminal ganglia becomes increasingly prevalent in 
humans with age and affects a majority of adults. Infection with HSV-1 has been 
epidemiologically linked to several common chronic neuropsychiatric and neurodegenerative 
diseases. Experimental HSV-1 infection of mice can lead to chronic behavioral and 
neurological deficits and chronic pain. While neuron injury and loss are well-documented 
consequences of the acute phase of infection, the pathologic consequences of latent HSV-1 
infection are poorly understood. The objective of this study was to determine whether latent 
HSV-1 infection can cause neuronal injury in mice. Trigeminal ganglia derived from adult 
BALB/c mice 1, 12 and 31 weeks after corneal HSV-1 inoculation were analyzed for evidence 
of productive or latent HSV-1 infection, inflammation and changes in neuron size, density and 
number. Latent HSV-1 infection between 12 and 31 weeks after corneal virus inoculation was 
associated with inflammation and progressive deficits in mean neuron diameter, neuronal 
nucleus diameter, neuron density and neuron number in the TG relative to mock-infected 
controls. The extent of neuronal injury during latent infection correlated with the extent of 
inflammation. Our observations demonstrate that latent HSV-1 infection is associated with 
progressive neuronal pathology and may lead to a better understanding of the role of HSV-1 
infections in chronic neurological diseases. 
To better understand melanoma resistance to herpes simplex virus type-1 (HSV-1)-
mediated oncolysis, traditional two-dimensional (2D) monolayer cultures and extracellular 
matrix containing (ECM) three-dimensional (3D) cultures of OCM1 and C918 uveal 
melanoma cells were infected with an HSV-1 strain that expresses the green fluorescent 
protein (GFP) marker during replication. Although 2D cultures were completely destroyed 
within a few days of HSV-1 inoculation, viable GFP-negative tumor cells remained detectable 
in 3D cultures for several weeks. Tumor cells with increased resistance to HSV-1 included 
cells that formed vasculogenic mimicry patterns and multicellular spheroids and cells that 
invaded Matrigel individually. Mechanisms of tumor resistance against HSV-1 in the 3D 
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environment included impaired virus spread in the ECM and ECM-mediated inhibition of 
viral replication after viral entry into tumor cells. Our observations also suggested that HSV-1 
established latent infection in some tumor cells present in multicellular spheroids and that this 
could revert to productive viral infection when the tumor growth pattern changed. These 
findings indicate that 3D tumor cell cultures can be used to identify distinct tumor cell 
populations with latent HSV-1 infection and to explore mechanisms of ECM-mediated tumor 
resistance to oncolytic virotherapy. 
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7. ÖSSZEFOGLALÁS 
 
Munkánk során két szempontból vizsgáltuk a humán herpesz szimplex-1 (HSV-1) által 
létrehozott látens (lappangó, rejtett) fertőzést; in vivo és in vitro modell rendszerekben. 
A Herpesviridae család nagy és változatos csoportot alkot, a csoport tagjai a 
főemlősöktől a halakig bezáróan okoznak betegségeket. Biológiai tulajdonságaik alapján a 
Herpesviridae családot további három alcsaládra lehet osztani; Alphaherpesvirinae, 
Betaherpesvirinae és Gammaherpesvirinae. Az orvosi szempontból jelentős HSV-1 és HSV-2 
az Alphaherpesvirinae alcsaládba tartozik. Közös jellemzőik, hogy viszonylag rövid 
reprodukciós ciklusra képesek, gyorsan terjednek sejttenyészetben, hatékonyan elpusztítják a 
fertőzött sejteket és képesek létrehozni látens fertőzést elsősorban, de nem kizárólag, az érző 
idegdúcokban. A herpeszfertőzés a sérült bőr vagy nyálkahártya hámsejtjeiben megy végbe, 
az elsődleges fertőzés gyakran a korai gyermekkorban történik. A vírus a hámsejtekben 
szaporodik, a fertőzés gyakran tünetmentes, de előfordulhat, hogy hólyagok jelennek meg a 
nyálkahártyán, melyek végül fekélyekké alakulnak a fertőzés területén. Az elsődleges 
fertőzést követően, mely a hámsejtek pusztulásával jár, a vírus az érzőideg-végződésekbe jut, 
majd az idegnyúlványokon keresztül a gerincvelő hátsó gyöki ganglionjaiban telepszik meg, 
ahol lítikus (a sejt pusztulásához vezető) vagy látens (élethosszig tartó lappangás) virális 
génexpresszió következik be.  
A látens fertőzés alatt az idegdúcban kevés a kimutatható virális fehérje, a virális 
genomról történő átírás korlátozódik a látencia-asszociált transzkriptumokra (LATs). Nem 
ismert, hogy a látens HSV-1 fertőzés maga, vagy az ismételt reaktivációs események és az 
ehhez kapcsolódó gyulladásos válasz áll-e az idegdúcok károsodása mögött. A trigeminális 
ganglionokban található látens HSV-1 fertőzés a kor előrehaladtával egyre elterjedtebb és 
érinti a felnőttek többségét. A HSV-1 fertőzés járványtanilag kapcsolható számos idült 
neuropszichiátriai és neurodegeneratív betegséghez. Kísérleti körülmények között a  HSV-1 
fertőzés egerekben vezethet idült viselkedési és idegrendszeri károsodáshoz, illetve krónikus 
fájdalomhoz. Míg az idegsejtek károsodása jól dokumentált következménye a fertőzés heveny 
szakaszának, a látens fertőzés patológiás következményei kevésbé ismertek. Kutatásunk célja 
annak megállapítása volt, hogy a látens HSV-1 fertőzés okozhat-e idegsejt károsodást az 
egerek trigeminus idegdúcaiban. Felnőtt BALB/c egerekből származó trigeminális 
idegdúcokat vizsgáltunk  1, 12 és 31 héttel a szaruhartyán keresztüli HSV-1 fertőzést 
követően. Vizsgáltuk a fertőzés produktív vagy látens jellegét, illetve azt, hogy milyen 
változások történtek a neuronok méretét, sűrűségét és számát illetően. A látens HSV-1 
50 
fertőzés során, 12 és 31 héttel a szaruhártya vírusfertőzését követően fokozódó csökkenést 
tapasztatnunk az idegsejtek átmérőjében, az idegsejtek sűrűségében illetve az idegsejtek 
számában a kontroll idegdúcokhoz képest. Megfigyeléseink azt mutatják, hogy látens HSV-1 
fertőzéshez progresszív idegsejt károsodás társul, ez hozzásegíthet a HSV-1 fertőzések 
krónikus neurológiai betegségekben betöltött szerepének jobb megértéséhez. 
A HSV-1 ezen felül egy ígéretes jelölt a vírus közvetített onkolitikus (daganat 
pusztító) terápia területén. Az onkolitikus HSV-1 terápia függ a vírus szaporodásától a 
daganatsejtekben, illetve fokozza a szervezet vírusellenes - és ez által daganatellenes - 
immunválaszát. Annak ellenére, hogy jelentős előrelépések történtek, a vírus közvetített 
onkolitikus terápia a mai napig kihívásokkal néz szembe. Bár kísérleti körülmények között, 
hagyományos egyrétegű, kétdimenziós daganatsejt-tenyészeteket használva hatékonyan lehet 
HSV-1 vírusokkal sejttenyeszeteket megsemmisíteni, elő szervezetben a tumor sejtek 
elpusztítása gyakran nem teljes. Ezen jelenség okai a mai napig nem tisztazottak. Azonban 
számos megfigyelés azt sugallja, hogy a potenciális problémák közé tartozik többek között az 
extracelluláris mátrix gátló hatása a daganatsejtek közötti vírusterjedésre, illetve a virális 
receptorok csökkent kifejeződése a különböző daganatsejt populációkban. Munkánk második 
részben a HSV-1 által közvetített onkolízist vizsgáltuk két melanoma (rosszindulatú 
festéksejtes daganat) sejtvonal (OCM1 és C918) tanulmányozásával. Hogy bővebb betekintést 
nyerjünk a melanoma sejtek HSV-1 által közvetített onkolízissel szembeni ellenállásának 
folyamatába, egyrétegű/kétdimenziós és extracelluláris mátrixot tartalmazó háromdimenziós 
sejttenyészeteket fertőztünk meg egy módosított HSV-1 vírus törzzsel, mely replikációja 
során zöld fluoreszcens fehérjét fejez ki. Bár a kétdimenziós sejttenyészetek a HSV-1 fertőzés 
után néhány napon belül teljesen elpusztultak, a háromdimenziós sejtkultúrákban életképes és 
GFP-negatív tumor sejtek maradtak megfigyelhetőek a HSV-1 fertőzést követően. Azon 
tumor sejtek, melyek  fokozott ellenállást tanúsítottak a HSV-1 fertőzéssel szemben, 
jellegzetes növekedési formákat mutattak, úgynevezett vasculogenezist utánzó növekedési 
mintázatot követtek, illetve több sejtből álló gömböcskéket (spheroidok) formáltak. 
Háromdimenziós környezetben a tumor sejtek túlélését a következő mechanizmusok 
segíthetik elő: a vírus terjedésének csökkenése az extracelluláris mátrixban, illetve az 
extracelluláris mátrix által kiváltott vírusszaporodás gátlása. Megfigyeléseink azt mutatják, 
hogy a HSV-1 látens fertőzést hozott létre néhány spheroidban és ez a látens fertőzés 
produktív formát öltött, mikor a daganatsejtek növekedési mintázata megváltozott. 
Eredmények azt mutatják, hogy a háromdimenziós tumorsejt-tenyészetek jól használhatók 
különböző, látens HSV-1 fertőzést tartalmazó tumorsejt-populáció azonosítására, illetve 
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annak további vizsgálatára, úgymint az extracelluláris matrix milyen mechanizmusokkal 
befolyásolja az onkolitikus vírus terápia hatékonyságát. 
  
52 
8. REFERENCES 
[1] Field's Virology, Sixth edition ed., Lippincott Williams & Willkins, 2013. 
[2] L. Collier, J. Oxford, Human Virology, Third edition ed., Oxford University Press, 2006. 
[3] A. Bosque, V. Planelles, Induction of HIV-1 latency and reactivation in primary memory 
CD4+ T cells, Blood, 113 (2009) 58-65. 
[4] M. Ranzani, S. Annunziato, D.J. Adams, E. Montini, Cancer gene discovery: exploiting 
insertional mutagenesis, Molecular cancer research : MCR, 11 (2013) 1141-1158. 
[5] B. Roizman, L.E. Carmichael, F. Deinhardt, G. de-The, A.J. Nahmias, W. Plowright, F. 
Rapp, P. Sheldrick, M. Takahashi, K. Wolf, Herpesviridae. Definition, provisional 
nomenclature, and taxonomy. The Herpesvirus Study Group, the International Committee on 
Taxonomy of Viruses, Intervirology, 16 (1981) 201-217. 
[6] D. Shukla, P.G. Spear, Herpesviruses and heparan sulfate: an intimate relationship in aid 
of viral entry, J Clin Invest, 108 (2001) 503-510. 
[7] K. Grunewald, P. Desai, D.C. Winkler, J.B. Heymann, D.M. Belnap, W. Baumeister, A.C. 
Steven, Three-dimensional structure of herpes simplex virus from cryo-electron tomography, 
Science, 302 (2003) 1396-1398. 
[8] T.J. Liesegang, Biology and molecular aspects of herpes simplex and varicella-zoster virus 
infections, Ophthalmology, 99 (1992) 781-799. 
[9] B. Roizmann, R.C. Desrosiers, B. Fleckenstein, C. Lopez, A.C. Minson, M.J. Studdert, 
The family Herpesviridae: an update. The Herpesvirus Study Group of the International 
Committee on Taxonomy of Viruses, Archives of virology, 123 (1992) 425-449. 
53 
[10] J.P. Quinn, R.G. Dalziel, A.A. Nash, Herpes virus latency in sensory ganglia--a 
comparison with endogenous neuronal gene expression, Progress in neurobiology, 60 (2000) 
167-179. 
[11] L. Corey, P.G. Spear, Infections with herpes simplex viruses (2), N Engl J Med, 314 
(1986) 749-757. 
[12] D.A. Scott, W.A. Coulter, P.A. Biagioni, H.O. O'Neill, P.J. Lamey, Detection of herpes 
simplex virus type 1 shedding in the oral cavity by polymerase chain reaction and enzyme-
linked immunosorbent assay at the prodromal stage of recrudescent herpes labialis, Journal of 
oral pathology & medicine : official publication of the International Association of Oral 
Pathologists and the American Academy of Oral Pathology, 26 (1997) 305-309. 
[13] P.G. Arduino, S.R. Porter, Herpes Simplex Virus Type 1 infection: overview on relevant 
clinico-pathological features, Journal of oral pathology & medicine : official publication of 
the International Association of Oral Pathologists and the American Academy of Oral 
Pathology, 37 (2008) 107-121. 
[14] B.W.J. Mahy, M.H.V. Van Regenmortel, Encyclopedia of Virology, Third edition ed., 
Elsevier, 2008. 
[15] M. Devor, R. Govrin-Lippmann, Neurogenesis in adult rat dorsal root ganglia: on 
counting and the count, Somatosensory & motor research, 8 (1991) 9-12. 
[16] M. Devor, R. Govrin-Lippmann, I. Frank, P. Raber, Proliferation of primary sensory 
neurons in adult rat dorsal root ganglion and the kinetics of retrograde cell loss after sciatic 
nerve section, Somatosensory research, 3 (1985) 139-167. 
[17] P.G. Kennedy, A. Chaudhuri, Herpes simplex encephalitis, Journal of neurology, 
neurosurgery, and psychiatry, 73 (2002) 237-238. 
54 
[18] A. Sauerbrei, U. Eichhorn, G. Hottenrott, P. Wutzler, Virological diagnosis of herpes 
simplex encephalitis, Journal of clinical virology : the official publication of the Pan 
American Society for Clinical Virology, 17 (2000) 31-36. 
[19] J.R. Baringer, P. Pisani, Herpes simplex virus genomes in human nervous system tissue 
analyzed by polymerase chain reaction, Annals of neurology, 36 (1994) 823-829. 
[20] N.W. Fraser, W.C. Lawrence, Z. Wroblewska, D.H. Gilden, H. Koprowski, Herpes 
simplex type 1 DNA in human brain tissue, Proc Natl Acad Sci U S A, 78 (1981) 6461-6465. 
[21] R.F. Itzhaki, W.R. Lin, D. Shang, G.K. Wilcock, B. Faragher, G.A. Jamieson, Herpes 
simplex virus type 1 in brain and risk of Alzheimer's disease, Lancet, 349 (1997) 241-244. 
[22] W. Liedtke, B. Opalka, C.W. Zimmermann, E. Lignitz, Age distribution of latent herpes 
simplex virus 1 and varicella-zoster virus genome in human nervous tissue, Journal of the 
neurological sciences, 116 (1993) 6-11. 
[23] J.R. Baringer, P. Swoveland, Recovery of herpes-simplex virus from human trigeminal 
ganglions, N Engl J Med, 288 (1973) 648-650. 
[24] K.D. Croen, J.M. Ostrove, L.J. Dragovic, S.E. Straus, Patterns of gene expression and 
sites of latency in human nerve ganglia are different for varicella-zoster and herpes simplex 
viruses, Proc Natl Acad Sci U S A, 85 (1988) 9773-9777. 
[25] I. Steiner, J.G. Spivack, D.R. O'Boyle, 2nd, E. Lavi, N.W. Fraser, Latent herpes simplex 
virus type 1 transcription in human trigeminal ganglia, J Virol, 62 (1988) 3493-3496. 
[26] J.G. Stevens, L. Haarr, D.D. Porter, M.L. Cook, E.K. Wagner, Prominence of the herpes 
simplex virus latency-associated transcript in trigeminal ganglia from seropositive humans, 
The Journal of infectious diseases, 158 (1988) 117-123. 
55 
[27] P.R. Krause, K.D. Croen, S.E. Straus, J.M. Ostrove, Detection and preliminary 
characterization of herpes simplex virus type 1 transcripts in latently infected human 
trigeminal ganglia, J Virol, 62 (1988) 4819-4823. 
[28] D. Theil, T. Derfuss, I. Paripovic, S. Herberger, E. Meinl, O. Schueler, M. Strupp, V. 
Arbusow, T. Brandt, Latent herpesvirus infection in human trigeminal ganglia causes chronic 
immune response, Am J Pathol, 163 (2003) 2179-2184. 
[29] Z.S. Guo, S.H. Thorne, D.L. Bartlett, Oncolytic virotherapy: molecular targets in tumor-
selective replication and carrier cell-mediated delivery of oncolytic viruses, Biochimica et 
biophysica acta, 1785 (2008) 217-231. 
[30] T.C. Liu, D. Kirn, Gene therapy progress and prospects cancer: oncolytic viruses, Gene 
therapy, 15 (2008) 877-884. 
[31] D.S. Latchman, Herpes simplex virus-based vectors for the treatment of cancer and 
neurodegenerative disease, Current opinion in molecular therapeutics, 7 (2005) 415-418. 
[32] Y. Shen, J. Nemunaitis, Herpes simplex virus 1 (HSV-1) for cancer treatment, Cancer 
gene therapy, 13 (2006) 975-992. 
[33] S. Varghese, S.D. Rabkin, Oncolytic herpes simplex virus vectors for cancer virotherapy, 
Cancer gene therapy, 9 (2002) 967-978. 
[34] E.A. Chiocca, The host response to cancer virotherapy, Current opinion in molecular 
therapeutics, 10 (2008) 38-45. 
[35] F. Benencia, M.C. Courreges, N.W. Fraser, G. Coukos, Herpes virus oncolytic therapy 
reverses tumor immune dysfunction and facilitates tumor antigen presentation, Cancer 
biology & therapy, 7 (2008) 1194-1205. 
56 
[36] H. Fukuhara, T. Todo, Oncolytic herpes simplex virus type 1 and host immune 
responses, Current cancer drug targets, 7 (2007) 149-155. 
[37] C.G. Miller, N.W. Fraser, Requirement of an integrated immune response for successful 
neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model, Molecular 
therapy : the journal of the American Society of Gene Therapy, 7 (2003) 741-747. 
[38] G. Guzman, S. Oh, D. Shukla, H.H. Engelhard, T. Valyi-Nagy, Expression of entry 
receptor nectin-1 of herpes simplex virus 1 and/or herpes simplex virus 2 in normal and 
neoplastic human nervous system tissues, Acta virologica, 50 (2006) 59-66. 
[39] G. Guzman, S. Oh, D. Shukla, T. Valyi-Nagy, Nectin-1 expression in the normal and 
neoplastic human uterine cervix, Archives of pathology & laboratory medicine, 130 (2006) 
1193-1195. 
[40] D. Kolodkin-Gal, G. Zamir, Y. Edden, E. Pikarsky, A. Pikarsky, H. Haim, Y.S. Haviv, 
A. Panet, Herpes simplex virus type 1 preferentially targets human colon carcinoma: role of 
extracellular matrix, J Virol, 82 (2008) 999-1010. 
[41] M.A. Rueger, A. Winkeler, H. Miletic, C. Kaestle, R. Richter, G. Schneider, R. Hilker, 
M.T. Heneka, R.I. Ernestus, J.A. Hampl, C. Fraefel, A.H. Jacobs, Variability in infectivity of 
primary cell cultures of human brain tumors with HSV-1 amplicon vectors, Gene therapy, 12 
(2005) 588-596. 
[42] A. Abbott, Cell culture: biology's new dimension, Nature, 424 (2003) 870-872. 
[43] M.J. Friedrich, Studying cancer in 3 dimensions: 3-D models foster new insights into 
tumorigenesis, Jama, 290 (2003) 1977-1979. 
[44] S. Ghosh, G.C. Spagnoli, I. Martin, S. Ploegert, P. Demougin, M. Heberer, A. Reschner, 
Three-dimensional culture of melanoma cells profoundly affects gene expression profile: a 
high density oligonucleotide array study, Journal of cellular physiology, 204 (2005) 522-531. 
57 
[45] K.S. Smalley, M. Lioni, M. Herlyn, Life isn't flat: taking cancer biology to the next 
dimension, In vitro cellular & developmental biology. Animal, 42 (2006) 242-247. 
[46] R. Schmidmaier, P. Baumann, ANTI-ADHESION evolves to a promising therapeutic 
concept in oncology, Current medicinal chemistry, 15 (2008) 978-990. 
[47] E.K. Wagner, D.C. Bloom, Experimental investigation of herpes simplex virus latency, 
Clinical microbiology reviews, 10 (1997) 419-443. 
[48] F. Xu, K.J. Burg, Three-dimensional polymeric systems for cancer cell studies, 
Cytotechnology, 54 (2007) 135-143. 
[49] T. Jacks, R.A. Weinberg, Taking the study of cancer cell survival to a new dimension, 
Cell, 111 (2002) 923-925. 
[50] C.O. Yun, Overcoming the extracellular matrix barrier to improve intratumoral spread 
and therapeutic potential of oncolytic virotherapy, Current opinion in molecular therapeutics, 
10 (2008) 356-361. 
[51] N. Shimony, R. Gorodetsky, G. Marx, D. Gal, R. Rivkin, A. Ben-Ari, A. Landsman, Y.S. 
Haviv, Fibrin microbeads (FMB) as a 3D platform for kidney gene and cell therapy, Kidney 
international, 69 (2006) 625-633. 
[52] K. Valyi-Nagy, R. Folberg, T. Valyi-Nagy, A.J. Maniotis, Role of tumor invasiveness, 
the extracellular matrix, and chromatin sequestration in the susceptibility of uveal melanoma 
to herpes simplex virus type 1, Experimental eye research, 84 (2007) 991-1000. 
[53] A.G. Armien, S. Hu, M.R. Little, N. Robinson, J.R. Lokensgard, W.C. Low, M.C. 
Cheeran, Chronic cortical and subcortical pathology with associated neurological deficits 
ensuing experimental herpes encephalitis, Brain pathology, 20 (2010) 738-750. 
58 
[54] L.S. Crnic, L.I. Pizer, Behavioral effects of neonatal herpes simplex type 1 infection of 
mice, Neurotoxicology and teratology, 10 (1988) 381-386. 
[55] L.T. Feldman, A.R. Ellison, C.C. Voytek, L. Yang, P. Krause, T.P. Margolis, 
Spontaneous molecular reactivation of herpes simplex virus type 1 latency in mice, Proc Natl 
Acad Sci U S A, 99 (2002) 978-983. 
[56] R. Mahalingam, M.C. Wellish, A.N. Dueland, R.J. Cohrs, D.H. Gilden, Localization of 
herpes simplex virus and varicella zoster virus DNA in human ganglia, Annals of neurology, 
31 (1992) 444-448. 
[57] J.H. McLean, M.T. Shipley, D.I. Bernstein, D. Corbett, Selective lesions of neural 
pathways following viral inoculation of the olfactory bulb, Experimental neurology, 122 
(1993) 209-222. 
[58] D. Milatovic, Y. Zhang, S.J. Olson, K.S. Montine, L.J. Roberts, 2nd, J.D. Morrow, T.J. 
Montine, T.S. Dermody, T. Valyi-Nagy, Herpes simplex virus type 1 encephalitis is 
associated with elevated levels of F2-isoprostanes and F4-neuroprostanes, Journal of 
neurovirology, 8 (2002) 295-305. 
[59] T. Valyi-Nagy, T.S. Dermody, Role of oxidative damage in the pathogenesis of viral 
infections of the nervous system, Histology and histopathology, 20 (2005) 957-967. 
[60] S.M. Brown, D.A. Ritchie, J.H. Subak-Sharpe, Genetic studies with herpes simplex virus 
type 1. The isolation of temperature-sensitive mutants, their arrangement into 
complementation groups and recombination analysis leading to a linkage map, J Gen Virol, 
18 (1973) 329-346. 
[61] T. Valyi-Nagy, S.L. Deshmane, J.G. Spivack, I. Steiner, C.I. Ace, C.M. Preston, N.W. 
Fraser, Investigation of herpes simplex virus type 1 (HSV-1) gene expression and DNA 
synthesis during the establishment of latent infection by an HSV-1 mutant, in1814, that does 
not replicate in mouse trigeminal ganglia, J Gen Virol, 72 ( Pt 3) (1991) 641-649. 
59 
[62] T. Tandrup, Unbiased estimates of number and size of rat dorsal root ganglion cells in 
studies of structure and cell survival, J Neurocytol, 33 (2004) 173-192. 
[63] P. Desai, S. Person, Incorporation of the green fluorescent protein into the herpes simplex 
virus type 1 capsid, J Virol, 72 (1998) 7563-7568. 
[64] A.J. Maniotis, R. Folberg, A. Hess, E.A. Seftor, L.M. Gardner, J. Pe'er, J.M. Trent, P.S. 
Meltzer, M.J. Hendrix, Vascular channel formation by human melanoma cells in vivo and in 
vitro: vasculogenic mimicry, Am J Pathol, 155 (1999) 739-752. 
[65] A. Gil, A. Gonzalez, R. Dal-Re, P. Ortega, V. Dominguez, Prevalence of antibodies 
against varicella zoster, herpes simplex (types 1 and 2), hepatitis B and hepatitis A viruses 
among Spanish adolescents, The Journal of infection, 36 (1998) 53-56. 
[66] R. Piacentini, G. De Chiara, D.D. Li Puma, C. Ripoli, M.E. Marcocci, E. Garaci, A.T. 
Palamara, C. Grassi, HSV-1 and Alzheimer's disease: more than a hypothesis, Frontiers in 
pharmacology, 5 (2014) 97. 
[67] G. De Chiara, M.E. Marcocci, R. Sgarbanti, L. Civitelli, C. Ripoli, R. Piacentini, E. 
Garaci, C. Grassi, A.T. Palamara, Infectious agents and neurodegeneration, Molecular 
neurobiology, 46 (2012) 614-638. 
[68] A. Jacobs, X.O. Breakefield, C. Fraefel, HSV-1-based vectors for gene therapy of 
neurological diseases and brain tumors: part I. HSV-1 structure, replication and pathogenesis, 
Neoplasia, 1 (1999) 387-401. 
[69] T. Cecchini, R. Cuppini, S. Ciaroni, P. Barili, R. De Matteis, P. Del Grande, Changes in 
the number of primary sensory neurons in normal and vitamin-E-deficient rats during aging, 
Somatosensory & motor research, 12 (1995) 317-327. 
60 
[70] S. Ciaroni, T. Cecchini, R. Cuppini, P. Ferri, P. Ambrogini, C. Bruno, P. Del Grande, Are 
there proliferating neuronal precursors in adult rat dorsal root ganglia?, Neuroscience letters, 
281 (2000) 69-71. 
[71] M. Devor, R. Govrin-Lippmann, Neurogenesis in adult rat dorsal root ganglia, 
Neuroscience letters, 61 (1985) 189-194. 
[72] A. Lagares, H.Y. Li, X.F. Zhou, C. Avendano, Primary sensory neuron addition in the 
adult rat trigeminal ganglion: evidence for neural crest glio-neuronal precursor maturation, 
The Journal of neuroscience : the official journal of the Society for Neuroscience, 27 (2007) 
7939-7953. 
[73] G.J. Popken, P.B. Farel, Sensory neuron number in neonatal and adult rats estimated by 
means of stereologic and profile-based methods, The Journal of comparative neurology, 386 
(1997) 8-15. 
[74] P.B. Farel, Late differentiation contributes to the apparent increase in sensory neuron 
number in juvenile rat, Brain research. Developmental brain research, 144 (2003) 91-98. 
[75] C.M. Preston, Repression of viral transcription during herpes simplex virus latency, J 
Gen Virol, 81 (2000) 1-19. 
[76] T. Valyi-Nagy, S.J. Olson, K. Valyi-Nagy, T.J. Montine, T.S. Dermody, Herpes simplex 
virus type 1 latency in the murine nervous system is associated with oxidative damage to 
neurons, Virology, 278 (2000) 309-321. 
[77] B. Roizman, R.J. Whitley, The nine ages of herpes simplex virus, Herpes : the journal of 
the IHMF, 8 (2001) 23-27. 
[78] M. Simpson-Holley, R.C. Colgrove, G. Nalepa, J.W. Harper, D.M. Knipe, Identification 
and functional evaluation of cellular and viral factors involved in the alteration of nuclear 
architecture during herpes simplex virus 1 infection, J Virol, 79 (2005) 12840-12851. 
61 
[79] R. Whitley, Herpes simplex viruses., in: K.D.M. Fields B N, Howley P M (Ed.) Fields 
Virology, Philadelphia : Lippincott Williams & Wilkins, 2001, pp. 2461-2509. 
[80] M.F. Kramer, W.J. Cook, F.P. Roth, J. Zhu, H. Holman, D.M. Knipe, D.M. Coen, Latent 
herpes simplex virus infection of sensory neurons alters neuronal gene expression, J Virol, 77 
(2003) 9533-9541. 
[81] A. Sasaki, T. Mabuchi, K. Serizawa, I. Takasaki, T. Andoh, K. Shiraki, S. Ito, Y. 
Kuraishi, Different roles of nitric oxide synthase-1 and -2 between herpetic and postherpetic 
allodynia in mice, Neuroscience, 150 (2007) 459-466. 
[82] M. Sato-Takeda, I. Takasaki, K. Takeda, A. Sasaki, T. Andoh, H. Nojima, K. Shiraki, Y. 
Kuraishi, K. Hanaoka, K. Tokunaga, T. Yabe, Major histocompatibility complex haplotype is 
associated with postherpetic pain in mice, Anesthesiology, 104 (2006) 1063-1069. 
[83] I. Takasaki, H. Nojima, K. Shiraki, Y. Sugimoto, A. Ichikawa, F. Ushikubi, S. Narumiya, 
Y. Kuraishi, Involvement of cyclooxygenase-2 and EP3 prostaglandin receptor in acute 
herpetic but not postherpetic pain in mice, Neuropharmacology, 49 (2005) 283-292. 
[84] S.L. Buka, T.D. Cannon, E.F. Torrey, R.H. Yolken, D. Collaborative Study Group on the 
Perinatal Origins of Severe Psychiatric, Maternal exposure to herpes simplex virus and risk of 
psychosis among adult offspring, Biological psychiatry, 63 (2008) 809-815. 
[85] S.L. Buka, M.T. Tsuang, E.F. Torrey, M.A. Klebanoff, D. Bernstein, R.H. Yolken, 
Maternal infections and subsequent psychosis among offspring, Archives of general 
psychiatry, 58 (2001) 1032-1037. 
[86] F.B. Dickerson, J.J. Boronow, C. Stallings, A.E. Origoni, S. Cole, B. Krivogorsky, R.H. 
Yolken, Infection with herpes simplex virus type 1 is associated with cognitive deficits in 
bipolar disorder, Biological psychiatry, 55 (2004) 588-593. 
62 
[87] D. Krause, J. Matz, E. Weidinger, J. Wagner, A. Wildenauer, M. Obermeier, M. Riedel, 
N. Muller, The association of infectious agents and schizophrenia, The world journal of 
biological psychiatry : the official journal of the World Federation of Societies of Biological 
Psychiatry, 11 (2010) 739-743. 
[88] M. Mora, L. Quintero, R. Cardenas, H. Suarez-Roca, M. Zavala, N. Montiel, 
[Association between HSV-2 infection and serum anti-rat brain antibodies in patients with 
autism], Investigacion clinica, 50 (2009) 315-326. 
[89] D.J. Schretlen, T.D. Vannorsdall, J.M. Winicki, Y. Mushtaq, T. Hikida, A. Sawa, R.H. 
Yolken, F.B. Dickerson, N.G. Cascella, Neuroanatomic and cognitive abnormalities related to 
herpes simplex virus type 1 in schizophrenia, Schizophrenia research, 118 (2010) 224-231. 
[90] R. Yolken, Viruses and schizophrenia: a focus on herpes simplex virus, Herpes : the 
journal of the IHMF, 11 Suppl 2 (2004) 83A-88A. 
[91] R.A. Vescio, C.H. Redfern, T.J. Nelson, S. Ugoretz, P.H. Stern, R.M. Hoffman, In vivo-
like drug responses of human tumors growing in three-dimensional gel-supported primary 
culture, Proc Natl Acad Sci U S A, 84 (1987) 5029-5033. 
[92] R. Folberg, M.J. Hendrix, A.J. Maniotis, Vasculogenic mimicry and tumor angiogenesis, 
Am J Pathol, 156 (2000) 361-381. 
[93] R. Folberg, A.J. Maniotis, Vasculogenic mimicry, APMIS : acta pathologica, 
microbiologica, et immunologica Scandinavica, 112 (2004) 508-525. 
[94] T.D. McKee, P. Grandi, W. Mok, G. Alexandrakis, N. Insin, J.P. Zimmer, M.G. 
Bawendi, Y. Boucher, X.O. Breakefield, R.K. Jain, Degradation of fibrillar collagen in a 
human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus 
vector, Cancer research, 66 (2006) 2509-2513. 
63 
[95] Z. Yu, P.S. Adusumilli, D.P. Eisenberg, E. Darr, R.A. Ghossein, S. Li, S. Liu, B. Singh, 
J.P. Shah, Y. Fong, R.J. Wong, Nectin-1 expression by squamous cell carcinoma is a predictor 
of herpes oncolytic sensitivity, Molecular therapy : the journal of the American Society of 
Gene Therapy, 15 (2007) 103-113. 
[96] B.S. Weeks, R.S. Ramchandran, J.J. Hopkins, H.M. Friedman, Herpes simplex virus 
type-1 and -2 pathogenesis is restricted by the epidermal basement membrane, Archives of 
virology, 145 (2000) 385-396. 
[97] V.M. Weaver, S. Lelievre, J.N. Lakins, M.A. Chrenek, J.C. Jones, F. Giancotti, Z. Werb, 
M.J. Bissell, beta4 integrin-dependent formation of polarized three-dimensional architecture 
confers resistance to apoptosis in normal and malignant mammary epithelium, Cancer cell, 2 
(2002) 205-216. 
[98] V.M. Weaver, O.W. Petersen, F. Wang, C.A. Larabell, P. Briand, C. Damsky, M.J. 
Bissell, Reversion of the malignant phenotype of human breast cells in three-dimensional 
culture and in vivo by integrin blocking antibodies, J Cell Biol, 137 (1997) 231-245. 
[99] S.D. Valyi-Nagy T, Engelhard HH, Kavouras J,, S. P, Latency strategies of 
alphaherpesviruses: herpes simplex virus and varicella-zoster virus latency in neurons., 1st 
ed., Springer: New York, 2007. 
  
  
64 
Acknowledgements 
 
 
I would like to thank Dr. Valéria Endrész, Ph.D for her support and professional supervision. 
I wish to thank the Rosztoczy Foundation and Tibor Valyi-Nagy, MD, PhD for providing me 
the excellent opportunity to work at the Department of Pathology at University of Illinois at 
Chicago. 
My special thanks to my wife for her support and continuous encouragement. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
65 
 
 
 
 
 
 
 
Appendix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     I. 
R E S EARCH ART I C L E bpa_485 1..11
Chronic Progressive Deficits in Neuron Size, Density and
Number in the Trigeminal Ganglia of Mice Latently Infected
with Herpes Simplex Virus
Sandor Dosa1,7; Karla Castellanos1; Sarolta Bacsa2,8; Eva Gagyi1; S. Krisztian Kovacs1,7; Klara Valyi-Nagy1;
Deepak Shukla2,3; Terence S. Dermody4,5,6; Tibor Valyi-Nagy1
Departments of 1 Pathology, 2 Ophthalmology and Visual Sciences and 3 Microbiology and Immunology, University of Illinois at Chicago, College of
Medicine, Chicago, Ill.
Departments of 4 Pediatrics and 5 Microbiology and Immunology and 6 Elizabeth B. Lamb Center for Pediatric Research, Vanderbilt University School
of Medicine, Nashville, Tenn.
Departments of 7 Pathology and 8 Dermatology and Allergology, University of Szeged, Hungary.
Abstract
Numerous epidemiological studies have proposed a link between herpes simplex virus
(HSV) infection and several common chronic neuropsychiatric and neurodegenerative dis-
eases. Experimental HSV infection of mice can lead to chronic behavioral and neurological
deficits and chronic pain. While neuron injury and loss are well-documented consequences
of the acute phase of infection, the pathologic consequences of latent HSV infection are
poorly understood. To determine whether latent HSV infection can cause neuronal injury
in mice, trigeminal ganglia (TG) derived from adult BALB/c mice 1, 12 and 31 weeks after
corneal HSV type 1 (HSV-1) inoculation were analyzed for evidence of productive or latent
HSV-1 infection, inflammation and changes in neuron size, density and number. We found
that latent HSV-1 infection between 12 and 31 weeks after corneal virus inoculation was
associated with inflammation and progressive deficits in mean neuron diameter, neuronal
nucleus diameter, neuron density and neuron number in the TG relative to mock-infected
controls. The extent of neuronal injury during latent infection correlated with the extent of
inflammation. These studies demonstrate that latent HSV infection is associated with pro-
gressive neuronal pathology and may lead to a better understanding of the role of HSV
infections in chronic neurological diseases.
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INTRODUCTION
Primary infections with herpes simplex viruses HSV-1 and HSV-2
are rapidly controlled by immunocompetent individuals but result
in the establishment of viral latency in neurons primarily in periph-
eral sensory ganglia (60). Latent HSV-1 infection of the trigeminal
ganglia (TG) becomes increasingly prevalent in humans with age
and affects a majority of adults (2, 3, 36). This latent ganglionic
infection may serve as the source of virus for recurrent infections
of epithelial surfaces including the cornea and also for infections of
the central nervous system (CNS) (60). HSVDNA is detectable at a
relatively high frequency in various sites of the adult human CNS
including the brainstem, olfactory bulbs and temporal lobe (2, 19,
23, 31), although it is not clear whether virus can reactivate in the
CNS.
Interestingly, infections with HSV have been epidemiologically
linked to some of the most common chronic neuropsychiatric
and neurodegenerative diseases in humans including Alzheimer’s
disease, autism and schizophrenia (5, 6, 16, 23, 28, 38, 45, 47, 61).
As HSV replication is usually not detectable in the nervous system
of persons affected by these disorders, it has been proposed that
latent HSV infection or periodic HSV reactivation events contrib-
ute to disease pathogenesis (5, 6, 16, 23, 28, 38, 45, 47, 61).
The pathological consequences of HSV-1 latency and reactiva-
tion in the human nervous system are not well understood. During
latent HSV infection in the TG, there is little detectable viral
protein and infectious virus production (3, 19). HSV transcripts
during latency are restricted to neurons, with in situ hybridization
signals strongest over nuclei (12, 49, 50). Abundant transcription
from the viral genome appears to be restricted to the latency-
associated transcripts (LATs) that map to repeat sequences flanking
the unique long region (12, 29, 49, 50). Interestingly, HSV latency
in humanTG is associated with chronic inflammation (53). It is not
known whether latent HSV-1 infection or repeated reactivation
events in the human TG cause significant peripheral nervous
system injury including neuronal loss.
As many aspects of HSV-1 pathogenesis can not be efficiently
studied in humans, experimental animal models of HSV-1 latency
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have been widely used (41, 42, 59). One of these models involves
corneal inoculation of mice with HSV-1 with the consequent
establishment of latent infection in the TG. Many aspects of
this model are similar to the pathogenesis of HSV-1 latency
in humans (59). HSV-1 inoculation leads to viral replication
in the cornea, followed by spread of virus via neural pathways
to the TG and CNS, where virus may replicate and cause gang-
lionitis and encephalitis. Animals surviving the acute phase
of infection do not display signs or symptoms of encephalitis,
and infectious virus is not detectable in the nervous system by
approximately 2 weeks following corneal inoculation. However,
virus is not cleared from infected animals, as HSV establishes
latency in neurons of the TG. HSV-1 latent infection in murine TG
neurons shows features similar to those seen in humans. In latently
infected mice, viral genomic DNA is present in neuronal nuclei,
abundant viral gene expression is limited to the LATs and viral
proteins or infectious virus are not detectable. HSV may reactivate
spontaneously in the nervous system of latently infected mice.
However, these reactivation events aremuch less frequent than those
in humans. Reactivation also can be experimentally induced inmice
by a variety of stressful stimuli (41, 42, 59).
While mice surviving the acute phase of experimental HSV
infection do not show signs and symptoms of encephalitis, numer-
ous studies documented chronic behavioral and neurological defi-
cits and chronic pain in these animals (1, 11, 34, 35, 43, 44, 51).
While neuron injury and loss are well documented, consequences
of the acute phase of infection (20, 22, 39, 54), the pathologic
consequences of latent HSV infection are poorly understood.
HSV-1 latency in the murine TG is associated with chronic
inflammation and immune activation. Mononuclear inflammatory
cells including CD4+ T cells, CD8+ T cells and macrophages
persist in latently infected TG, and several cytokines including
interferon-g and tumor necrosis factor-a as well as nitric oxide are
present at elevated levels in these tissues (7, 9, 21, 24, 26, 32, 33,
46, 57). Infiltrating lymphocytes may function in the maintenance
of HSV-1 latency by suppressing viral replication by non-cytolytic
mechanisms (25).
It has been suggested that HSV-1 latent infection or latency-
associated chronic inflammatory changes cause tissue injury and
resultant TG dysfunction. In mice, HSV latency is associated with
modest but consistently detectable oxidative damage including oxi-
dative marks to nucleic acid, protein and lipid in both neurons and
non-neuronal cells in the TG (37, 55, 57). The pathophysiological
changes associated with latent infection also are associated with
alterations in gene expression (27).
In this study, we used quantitative morphometric analyses to test
whether latent HSV-1 infection affects mean neuron diameter, neu-
ronal nucleusdiameter, neurondensity andneuronnumber in theTG
of mice. For these studies, we used TG tissues obtained from
BALB/cmice 1, 12 and31weeks after corneal inoculation ofHSV-1
at 5 weeks of age. These tissues were previously demonstrated to
harbor productive HSV-1 infection at 1 week and latent HSV-1
infection at 12 and 31weeks after virus inoculation (57).The results
provide strong evidence that latent HSV-1 infection is associated
with chronic progressive deficits inmean neuron diameter, neuronal
nucleus diameter, neuron density and neuron number in the murine
TG.Thiswork provides a link betweenHSV latency and progressive
neural damage and establishes an experimental platform to explore
mechanisms of HSV-induced chronic neurological disease.
MATERIALS AND METHODS
Virus stocks
HSV-1 strain 17+(4) was propagated and titered by plaque assay
using baby hamster kidney (BHK) 21 clone 13 cells.
Inoculation of mice
Five (four to six)-week-old female BALB/c mice (Harlan, India-
napolis, IN) were inoculated with 1 ¥ 105 plaque-forming units
(PFU) of HSV-1 17+ per eye after corneal scarification using
Metofen anesthesia as previously described (57). Control mice
were inoculated with an equivalent volume of sterile tissue
culture medium using the same technique (mock infection). Mice
were followed daily for signs and symptoms of disease. Groups
of mice consisting of five or six randomly chosen HSV-1-infected
and mock-infected mice per treatment were euthanized at 1,
12 and 31 weeks after inoculation (at 5, 17 and 35 weeks of age),
and TG were aseptically removed. TG were excised by cutting the
trigeminal root at its entrance into the brainstem, the mandibular
branch at least 1 mm distally to the ganglion and the maxillary
branch at the level of the orbital fissure. Tissues were fixed in
paraformaldehyde–lysine–periodate fixate and embedded in par-
affin. Before the final embedding step, TG were randomly rotated
along their longitudinal axis, embedded in paraffin and sectioned.
Multiple sections encompassing the complete thickness of the
tissue blocks were processed for hematoxylin and eosin staining
for histologic evaluation, immunohistochemistry, in situ hybrid-
ization and morphometric studies. Animal husbandry and expe-
rimental procedures were performed in accordance with NIH
Public Health Service policy and approved by the Vanderbilt
University School of Medicine Institutional Animal Care and Use
Committee.
Immunohistochemistry for the detection of
HSV-1 proteins
Multiple 6-mm-thick tissue sections derived from representative
portions of the paraffin-embedded TG tissues were deparaffinized
with xylene and dehydrated through a series of graded ethanols.
HSV-1 antigens were detected using a 1:1000 dilution of a
polyclonal anti-HSV-1 antiserum raised in a rabbit (DAKO,
Carpinteria, CA) as previously described (58).
In situ hybridization for HSV-1-LAT
gene expression
In situ hybridization was performed using a nick-translated 35S-
labeled DNA probe specific for HSV-1 LAT (Bst2Bst2 fragment)
and 6-mm-thick tissue sections according to previously described
techniques (56).
Determination of mean neuron diameter, neuron
nucleus diameter, neuron density, TG volume
and neuron number per TG
For the determination of mean neuron diameter and mean neuron
nucleus diameter, multiple 6-mm-thick tissue sections derived from
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representative portions of the paraffin-embedded TG tissues were
stained with hematoxylin, scanned at 200¥magnification using the
ImageScope® System (Aperio Technologies, Inc., Vista, CA) and
analyzed with the aid of Aperio image analysis software. The
largest diameter and the largest nuclear diameter of 100 randomly
chosen neurons in each TG were measured manually by an
observer blinded to the nature and time of inoculation. For each
time point and treatment group, measurements were made for 7 to
12 TG sections derived from five to six mice yielding 700 to 1200
measurements per group. Mean neuron diameter and neuronal
nucleus diameter and standard deviations were calculated for each
treatment type (HSV-1-inoculated or mock-inoculated) and each
time point (1, 12 and 31 weeks after inoculation).
For neuronal cell density measurements, multiple 20-mm-thick
sections derived from representative portions of the paraffin-
embedded TG tissues were cut and stained with hematoxylin and
viewed using a 60¥ objective on an Olympus BH-2 microscope
(Olympus Optical Co. Ltd, Tokyo, Japan) (magnification: 600¥).
For each time point and treatment group (infected or mock), five
TG (randomly selected left or right) from five mice were examined
using at least three sections of eachTG. Neurons were identified by
morphology based on the detection of nucleoli and Nissl substance
(52). Neuronal cell density determinations were made with the aid
of image analysis software (ImageJ, Research Service Branch,
National Institute of Mental Health, Bethesda, MD, USA), digital
video camera (Sony, Park Ridge, NJ, USA) and a computer system
according to a published stereological optical dissector method
(52). The dimensions of the dissector used were 50 ¥ 50 mm in the
x- and the y-axis. The guard area (the top and bottom of the histo-
logical section in which neurons were not counted to avoid errors)
was 5 mm; the optimal dissector’s height was 15 mm. Nuclei were
used as counting units. Neuronal density, that is the number of
neurons per unit volume of TG (neurons per volume, nv), was
determined with an optical dissector method using Tandrup’s
review concerning dorsal root ganglion as a guiding principle (52).
The total value of nv for a TG was then determined from:
n
Q
p a h
v
frame
=
−Σ
Σ ( )
where SQ- is the sum of the dissector neurons in the total dissector
volumes, a(frame) is the area of the counting frame, h is the height of
the optical dissector and p is the number a points per dissector.
Neuron density was determined for each examined TG separately,
and mean neuron density and standard deviation per treatment
group was then calculated.
The volume of TG was calculated using image analysis software
(ImageJ) and digital video camera (Sony) to draw manually the
contour of each analyzedTG section at a magnification of 5¥ and to
measure automatically its area in mm2. One of every 10 sections
derived from the whole thickness of theTGwas analyzed. The total
volume of ganglia was calculated by multiplying the surface area
by the thickness of the section and by the number of sections
included in the interval between the analyzed sections and sum-
marizing the calculated volumes for the whole TG. Mean TG
volume and standard deviation for each treatment group (HSV-1-
inoculated or mock-inoculated and 1, 12 and 31 weeks after inocu-
lation) was then calculated.
The number of neurons per TG was calculated based on neuron
density and TG volume as follows: N = nv ¥ V, where N corre-
sponds to neuron number per TG, nv stands for neuron density and
V forTG volume. Calculation was performed separately for fiveTG
in each treatment group. Mean neuron number perTG and standard
deviation for each treatment group (HSV-1-inoculated or mock-
inoculated and 1, 12 and 31 weeks after inoculation) was then
calculated.
Data analysis
Statistical analyses were performed with the STATISTICA soft-
ware (version 8.0, Tulsa, OK) for windows. Normality was tested
using the Kolmogorov–Smirnov test. All variables were normally
distributed. Homogeneity of variance was determined using F-test
and Levene’s test and was considered violated when this test
yielded P < 0.05. All variances were homogeneous; data were
assessed using independent samples T-test and repeated measures
analysis of variance (ANOVA) followed by Scheffe’s post hoc test.
Differences between the means were considered statistically sig-
nificant if P < 0.05. The results are expressed as mean standard
deviation (SD) values.
RESULTS
Characterization of TG tissues derived from
mice at 1, 12 and 31 weeks following corneal
HSV-1 inoculation
To obtain TG tissues at various stages of HSV-1 infection, mice
were inoculated on the cornea with either HSV-1 or sterile tissue
culture medium. Observations about consequent clinical symp-
toms and the detection of productive vs. latent HSV-1 infection
in the TG were reported previously (57). A minority of HSV-1-
infected mice demonstrated signs of encephalitis (agitation or
paralysis), and 13% of the animals died within 3 weeks of in-
fection. Animals surviving beyond 3 weeks of virus inoculation
demonstrated no signs of encephalitis and developed normally.
Groups of five to six randomly chosen HSV-1-infected and mock-
infected mice were euthanized at 1, 12 and 31 weeks after inocula-
tion. TG were aseptically removed from euthanized animals, and
tissues were processed for immunohistochemical staining for
HSV-1 antigen and in situ hybridization for LAT expression
to document acute or latent HSV-1 infection and to evaluate
for histopathologic evidence of inflammation (Figures 1–3). No
HSV-1 protein expression was detected in theTG of mock-infected
mice at any time point (Figure 1A,C,E). In five animals euthanized
1 week after HSV-1 inoculation, HSV-1 proteins were detected in
all 10 TG by immunostaining (Figure 1B), consistent with replica-
tion of HSV-1. HSV-1 proteins were detected in numerous cells that
by morphological criteria were neurons and non-neuronal cells. In
TG derived from animals euthanized at 12 and 31 weeks after
corneal HSV-1 inoculation, HSV-1 protein expression was not
detected in the TG derived from four out of five mice tested
(Figure 1D,F). One TG section at each time point demonstrated
very rare non-neuronal cells that stained for HSV-1 proteins (data
not shown).Abundant LATRNA expression was detected by in situ
hybridization in TG tissues of HSV-1-infected mice euthanized at
12 and 31 weeks after virus inoculation (Figure 2B). Sections of
TG stained with hematoxylin and eosin at 1, 12 and 31 weeks
after HSV-1 inoculation revealed chronic inflammatory changes
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(Figure 3B, D, F). Inflammation was not detected in the TG of
mock-infected animals (Figure 3A, C, E). These findings indicate
that mice examined at 1 week after virus inoculation were produc-
tively infected with HSV-1, whereas those examined at 12 and 31
weeks after inoculation were latently infected with the virus. Mar-
ginal HSV-1 expression in one mouse each at 12 and 31 weeks after
virus inoculation is consistent with rare focal HSV-1 reactivation.
In addition, both acute and latent HSV-1 infection in the murineTG
was associated with inflammation.
Mean neuron diameter, mean neuronal nucleus
diameter and the number of neurons increase in
the TG of mock-infected BALB/c mice
Mean neuron diameter and mean neuronal nucleus diameter gradu-
ally increased in the TG of control mice between 1 and 31 weeks
after mock infection (between 6 and 36 weeks of age) (Table 1).
Specifically, mean neuron diameters at 6, 17 and 36 weeks of age
were 22.74 5.2 mm (n = 700), 22.98 4.9 mm (n = 700) and
Figure 1. HSV-1 protein expression in
murine trigeminal ganglion (TG) tissues
following corneal inoculation of HSV-1 or
sterile medium (mock-infection) as detected
by immunohistochemistry. Brown staining
indicates HSV-1 proteins. HSV-1 protein
expression was not detected in TG derived
from mock-infected mice at 1 (A), 12 (C) or
31 (E) weeks after mock inoculation. HSV-1
protein expression in a neuron in a TG
derived from a mouse 1 week after corneal
HSV-1 inoculation (B). HSV-1 protein
expression was not detected in TG derived
from mice 12 (D) or 31 (F) weeks after
corneal HSV-1 inoculation.
Magnification = 400¥.
Figure 2. Detection of HSV-1 LAT in the
trigeminal ganglia (TG) of mice by in situ
hybridization. Accumulation of dark grains
indicates LAT accumulation. A. There was no
evidence of LAT expression in TG derived
from a mouse 31 weeks after corneal mock
inoculation. B. Numerous LAT-positive cells
in TG tissue derived from a mouse 31 weeks
after corneal HSV-1 inoculation.
Magnification = 200¥.
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25.16 5.0 mm (n = 900), respectively. Mean neuronal nucleus
diameters at 6, 17 and 36 weeks of age were 9.15 2.2 mm
(n = 700), 9.27 1.8 mm (n = 700) and 10.33 2.0 mm (n = 900),
respectively. Increases in mean neuron diameter and neuronal
nucleus diameter did not differ statistically between 6 and 17 weeks
(P = 0.3782 and 0.2794, respectively), but these differences were
statistically significant at 6 and 36 weeks and 17 and 36 weeks
(P < 0.0001). These findings are consistent with growth of TG
neurons during the observation interval.
Neuron density in theTG decreased, while TG volume increased
inmock-infectedmice during the period of observation.The combi-
nation of these changes resulted in a gradual increase in the mean
number of neurons perTG between 6 and 36 weeks of age (Table 1,
Figures 4–6). Neuron density was 5.64 0.2 ¥ 10-5 neurons per
mm3 at 6 weeks of age (n = 5) and decreased to 4.59 0.2 ¥ 10-5
neurons permm3by17weeks (n = 5,P = 0.000191).Neuron density
was 4.51 0.1 ¥ 10-5 neurons per mm3 at 36 weeks of age (n = 5),
which was not significantly less than that at 16 weeks (P = 0.99) but
significantly less than that at 6 weeks of age (P = 0.000082). Mean
TG volume was 0.33 0.03 mm3 at 6 weeks of age (n = 5),
0.53 0.04 mm3 at 17 weeks (n = 5) and 0.89 0.04 mm3 at 36
weeks of age (n = 5) (Table 1, Fig. 5). These increases were stati-
stically significant (6–16 weeks: P = 0.000006; 17–36 weeks:
P = 0.000005; 6– 36 weeks: P = 0.0000001). The mean number of
neurons perTGwas 18 600 1000 (n = 5), 24 250 1800 (n = 5)
and40 900 3100 (n = 5) at 6, 17 and36weeksof age, respectively
(Table 1, Fig. 6).These increaseswere statistically significant (6–16
weeks: P = 0.00054; 17–36 weeks: P = 0.000013; 6–36 weeks:
P = 0.000001). Thus, TG volume and neuron number per TG
increase, while neuron density decreases in theTG ofmice between
6 and 36weeks of age.
Productive HSV-1 infection in the TG of mice is
associated with increased mean neuron
diameter and neuronal nucleus diameter and
decreased neuron density
In the TG of mice euthanized 1 week after corneal HSV-1 inocula-
tion, mean neuron diameter and mean neuronal nucleus diameter
were greater than that detected in TG derived from mice 1 week
after mock infection (Table 1). Specifically, mean neuron diameter
1 week after HSV-1 inoculation was 23.94 5.2 mm (n = 1200) vs.
22.74 5.2 mm (n = 700) in age-matched mock-infected controls
(Table 1, P = 0.0001), a 5.27% increase (Table 2). Mean neuro-
nal nucleus diameter 1 week after HSV-1 inoculation was
9.58 2.0 mm (n = 1200) vs. 9.15 2.2 mm (n = 700) detected in
controls (Table 1, P = 0.0001), a 4.7% increase (Table 2). These
changes in mean neuron diameter and neuronal nucleus diameter
are consistent with the cytopathic effects associated with HSV-1
replication in a subset of the ganglionic neurons. Indeed, analysis
of TG sections derived from mice 1 week following virus inocula-
tion and immunostained for HSV-1 proteins indicated that mean
Figure 3. Inflammation in murine trigeminal
ganglion (TG) tissues following corneal
inoculation of HSV-1. No evidence of
inflammation in hematoxylin and
eosin–stained sections of trigeminal ganglia
(TG) derived from mice at 1 (A), 12 (C) or 31
(E) weeks after corneal mock inoculation.
Chronic inflammation in hematoxylin and
eosin–stained sections of trigeminal ganglia
(TG) derived from mice at 1 (B), 12 (D) and 31
(F) weeks after corneal HSV-1 inoculation.
Magnification = 100¥.
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neuron diameter and neuronal nucleus diameter were significantly
greater in HSV-1 protein expressing neurons than in HSV-1
antigen–negative neurons (P < 0.001). Specifically, mean neuron
diameter and neuronal nucleus diameter measurements were
31.10 6.36 mm (n = 27) and 14.22 2.32 mm (n = 12), respec-
tively, in HSV-1 antigen–positive neurons, while mean neuron
diameter and neuronal nucleus diameter were measured at
25.93 4.32 mm (n = 50) and 11.66 1.5 mm (n = 50), respec-
tively, in HSV-1 antigen–negative neurons.
Mean neuron density was 8.69% less (5.15 0.1 ¥ 10-5 neurons
per mm3, n = 5) in TG derived from HSV-1-inoculated mice than in
mock-infected controls (5.64 0.2 ¥ 10-5 neurons per mm3, n = 5)
1 week after inoculation (Tables 1 and 2, Figure 4, P = 0.002646).
Mean TG volume was similar [0.33 0.3 mm3 (n = 5) vs.
0.33 0.3 mm3 (n = 5)] in HSV-1- and mock-infected mice at 1
week after inoculation (Table 1, Figure 5). The mean number of
neurons per TG was 17 000 1400 (n = 5) in virus-infected vs.
18 600 1000 (n = 5) in mock-infectedTG (Table 1, Figure 6), an
8.61% decrease (Table 2). This decrease in neuron number per TG
did not reach statistical significance (P = 0.082395). Collectively,
these findings are consistent with neuron destruction by productive
HSV-1 infection in the TG.
Latent HSV-1 infection in the TG of mice is
associated with decreased mean neuron
diameter, neuronal nucleus diameter and
neuron density and number
In the TG of mice euthanized 12 weeks after corneal HSV-1 inocu-
lation (at 17 weeks of age), mean neuron diameter, mean neuronalTa
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Figure 4. Median and range of neuron density per trigeminal ganglion
(TG) in mice euthanized 1, 12 and 31 weeks after corneal inoculation
of HSV-1 or sterile medium (mock) at 6, 17 and 36 weeks of age.
TG number (n) was 5 for all time points and treatment groups.
Rectangles represent 25% to 75% quartiles. *P < 0.05; **P < 0.001;
***P < 0.0001.
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nucleus diameter, neuron density and mean neuron number per TG
were all significantly less than those in age-matched mock-infected
control mice (Tables 1 and 2, Figures 4 and 6). Specifically,
mean neuron diameter at 12 weeks after HSV-1 inoculation was
22.25 4.6 mm (n = 1000) vs. 22.98 4.9 mm (n = 700) detected
in age-matched mock-infected controls (Table 1, P = 0.0023), a
3.17% decrease (Table 2). Mean neuronal nucleus diameter at
12 weeks after HSV-1 inoculation was 9.07 1.8 mm (P = 1000)
vs. 9.27 1.8 mm (P = 700) in controls (Table 1, P = 0.0249),
a 2.15% reduction (Table 2). Neuron density was 8.94% less
(4.18 0.2 ¥ 10-5 neurons per mm3, n = 5) in TG derived from
HSV-1-infected mice in comparison with those from mock-
infected mice (4.59 0.2 ¥ 10-5 neurons per mm3, n = 5) at 12
weeks after inoculation (Table 1, Figure 4, P = 0.00458). Mean
TG volume did not differ significantly (0.53 0.03 vs.
0.53 0.04 mm3, n = 5 for each) in HSV-1- and mock-infected
mice at 12 weeks after inoculation (Table 1, Figure 5). However,
the mean number of neurons per TG was significantly less in
HSV-1-infected mice than in mock-infected mice at 12 weeks
after inoculation (Table 1, Figure 6). Specifically, the total number
of neurons was 21 280 2200 (n = 5) in virus-infected vs.
24 250 1800 (n = 5) in mock-infected TG (Table 1, Figures 6,
P = 0.04718), a 12.25% decrease (Table 2). Thus, neuron size and
number are decreased in the TG of mice 12 weeks after HSV-1
corneal inoculation.
In the TG of mice euthanized 31 weeks after corneal HSV-1
inoculation (at 36 weeks of age), mean neuron diameter, mean
neuronal nucleus diameter, neuron density and mean neuron
number per TG were all significantly less than those detected in
age-matched mock-infected control mice (Table 1, Figures 4 and
6). Specifically, mean neuron diameter at 31 weeks after HSV-1
inoculation was 23.55 5.4 mm (n = 1000) vs. 25.16 5.0 mm
(n = 900) in age-matched mock-infected controls (Table 1,
P = 0.0001), a 6.4% decrease (Table 2). Mean neuronal nucleus
diameter at 31 weeks after HSV-1 inoculation was 9.76 2.0 mm
(n = 1000) vs. 10.33 2.0 mm (n = 900) in controls (Table 1,
P = 0.0001), a 5.5% reduction (Table 2). Neuron density was
13.3% less (3.91 0.2 ¥ 10-5 neurons per mm3, n = 5) in TG
derived from HSV-1-infected mice in comparison with those from
mock-infected mice (4.51 0.1 ¥ 10-5 neurons per mm3, n = 5)
at 31 weeks after inoculation (Table 1, Figure 4, P = 0.000054).
Mean TG volume did not differ significantly (0.86 0.04, n = 5
vs. 0.89 0.04 mm3, n = 5) in HSV-1- and mock-infected mice
at 31 weeks after inoculation (Table 1, Figure 5). However, like the
TG from mice at 12 weeks after HSV-1 inoculation, the number
of neurons per TG was significantly less in HSV-1-infected
mice than in mock-infected mice at 31 weeks after inoculation
(Table 1, Figure 6). Specifically, the total number of neurons was
Figure 5. Median and range of trigeminal ganglion (TG) volume in mice
euthanized 1, 12 and 31 weeks after corneal inoculation of HSV-1 or
sterile medium (mock) at 6, 17 and 36 weeks of age. TG number (n) was
5 for all time points and treatment groups. Rectangles represent 25% to
75% quartiles. *P < 0.05; **P < 0.001; ***P < 0.0001.
Figure 6. Median and range of neuron number per trigeminal ganglion
(TG) in mice euthanized 1, 12 and 31 weeks after corneal inoculation of
HSV-1 or sterile medium (mock) at 6, 17 and 36 weeks of age. TG
number (n) was 5 for all time points and treatment groups. Rectangles
represent 25% to 75% quartiles. *P < 0.05; **P < 0.01.
Table 2. Percentage change in mean neuron diameter, mean neuronal
nucleus diameter, neuron density and mean neuron number per TG in
HSV-1-infected mice relative to age-matched mock-infected mice.
Age 6 weeks 17 weeks 36 weeks
Neuron diameter (infected/control) +5.27% -3.17% -6.4%
Neuron nucleus diameter
(infected/control)
+4.7% -2.15% -5.5%
Neuron density (infected/control) -8.69% -8.94% -13.3%
Neuron number per TG
(infected/control)
-8.61% -12.25% -17.9%
TG = trigeminal ganglion.
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33 620 1600 (n = 5) in virus-infected vs. 40 950 3100 (n = 5)
in mock-infected TG (Table 1, P = 0.0016), a 17.9% relative
decrease (Table 1, Figure 6).
Deficits in mean neuron diameter, neuron nucleus diameter,
neuron density and neuron number per TG relative to age-matched
mock-infected controls were all more substantial at 31 weeks than
at 12 weeks after corneal virus inoculation (Table 2).As only latent
HSV-1 infection was detected in TG neurons at 12 and 31 weeks
after corneal virus inoculation, the progressive deficits in neuron
size, density and number between these times are consistent with
chronic progressive neural injury during latent HSV-1 infection.
Decreased mean neuron diameter and neuronal
nucleus diameter correlate with the extent of
inflammation in the TG of mice latently
infected with HSV-1
To investigate the role of LAT expression and inflammation in the
detected changes of neuron morphology during latent infection,
the number of LAT expressing cells, mean neuron diameter, mean
neuronal nucleus diameter and the extent of inflammation were
determined in TG sections of four latently infected mice (Table 3).
As grains associated with LAT detection by in situ hybridization
did not allow precise morphometric analysis, the following
approach was used. The number of LAT expressing cells was
counted in one TG section derived from each mice, and mean
neuron diameter, mean neuronal nucleus diameter and the extent
of inflammation was determined in a neighboring hematoxylin-
stained TG section. The extent of inflammation was expressed as
the percentage of TG section area demonstrating inflammation.
The extent of neuronal injury during latent infection seemed to
correlate with the extent of inflammation but not with the number
of LAT-expressing neurons (Table 3). Specifically, mean neuron
diameter and mean neuronal nucleus diameter were the smallest in
the most inflamed TG and were the greatest in the least inflamed
TG. Intermediate mean neuron diameter and nucleus diameter
values were detected in two ganglia harboring intermediate levels
of inflammation. These findings suggest that decreased mean
neuron diameter and neuronal nucleus diameter correlate with
the extent of inflammation in the TG of mice latently infected
with HSV-1.
DISCUSSION
We show here using careful morphometric analyses that in healthy
adult mice, mean neuron diameter, mean neuron nucleus diameter,
TG volume andmean number of neurons perTG gradually increase
between 6 and 37 weeks of age. The detection of increasing neuron
diameter, neuronal nucleus diameter andTG volume is not surpris-
ing and consistent with normal growth of these mice. Our findings
of increasing neuron numbers in the TG of mock-infected mice are
similar to those made in several reports of gradually increasing
numbers of mature neurons in the sensory ganglia of healthy adult
rats (8, 10, 13–15, 30, 40). In rats, both ongoing neurogenesis
and maturation of undifferentiated or partially differentiated
post-mitotic cells have been proposed as possible mechanisms
for the observed increase in the number of mature neurons in
adult animals (8, 10, 13–15, 17, 30, 40). A similar situation may
be operant in mice.
Numerous previous studies indicate that corneal inoculation of
immunocompetent mice with HSV-1 is followed by virus replica-
tion in the TG for about 2 weeks, which in turn is followed by the
establishment of life-long HSV-1 latency in the TG (41, 59). Con-
sistent with these reports and our previous analyses of the TG
tissues used in this study (57), we detected productive HSV-1 infec-
tion in the TG at 1 week after virus inoculation and evidence of
latent HSV-1 infection in the TG at 12 and 31 weeks after virus
inoculation. In the TG of mice euthanized 1 week after corneal
HSV-1 inoculation, mean neuron diameter and mean neuronal
nucleus diameter increased, while neuron density and mean neuron
number per TG decreased relative to age-matched mock-infected
controls (Tables 1 and 2). These findings are not surprising as these
ganglia harbor productive HSV-1 infection, and HSV-1 replication
is associated with cytopathic effects that include cellular swelling
and nuclear enlargement (42, 48). Furthermore, neuronal death in
the TG of mice during the first few weeks of infection is well
documented (41, 42, 60), which would account for the decrease in
neuron number.
The key finding of our study is that in the TG of mice 12 and 31
weeks after HSV-1 inoculation (at 17 and 36 weeks of age), mean
neuron diameter, neuronal nucleus diameter, neuron density and
mean neuron number per TG were significantly less than those in
age-matched mock-infected control TG. Interestingly, the deficits
in neuron diameter, neuronal nucleus diameter, neuron density and
neuron number in latently infected TG were more substantial at 36
weeks than at 17 weeks of age (Table 2). It is possible that dimin-
ished neuron size and number at 12 weeks after corneal virus
inoculation is attributable to neuron destruction and delayed
neuron growth caused by productive HSV-1 infection during the
first weeks of infection. However, as only latent HSV-1 infection
was detected in TG neurons at 12 and 31 weeks after corneal virus
inoculation, the progressive reductions in neuron size and number
between these intervals are unlikely to occur as a consequence of
virus replication during the first few weeks of infection.
Mean neuron diameter, mean neuronal nucleus diameter and
mean neuron number per TG increased in absolute numbers
between 17 and 36 weeks in latently infected mice (Table 1).
However, these increases were substantially less than those in
mock-infected controls. Furthermore, the increases detected were
less than expected for resumption of normal TG growth at these
times. Resumption of normal TG growth would be expected to be
Table 3. Number of HSV-1 LAT+ cells per section, mean neuron diam-
eter, mean neuronal nucleus diameter and extent of inflammation in TG
sections derived from four mice euthanized 31 weeks after corneal
HSV-1 inoculation at 36 weeks of age.
Number of
LAT+ cells
Mean cell
diameter
(mm)  SD
Mean nucleus
diameter
(mm)  SD
Inflammation
(%)
TG #1 55 24.171  6.24 9.608  2.23 10.2
TG #2 161 23.65  4.49 9.645  1.74 8.6
TG #3 198 21.409  4.69 9.085  1.65 79
TG #4 29 22.497  5.33 9.441  1.58 21
HSV-1 LAT = herpes simplex virus-1 latency-associated transcript
expression as detected by in situ hybridization; SD = standard devia-
tion; Inflammation (%) = percent area of TG section demonstrating
inflammation.
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associated with stable or decreasing deficits in neuron size, density
and number in latently infected TG between 12 and 31 weeks
after virus inoculation (between 16 and 36 weeks of age) relative
to age-matched controls. However, these relative deficits all
increased during latency (Table 2). These findings indicate that
latent HSV-1 infection is associated with chronic progressive
deficits in neuron size, density and number in the nervous system
of an immunocompetent host.
Mechanisms by which latent HSV-1 infection leads to chronic
progressive alterations in neuron size, density and number in the
nervous system are not clear from our study. As spontaneous
HSV-1 reactivation occurs in latently infected mice (59, 60), albeit
rarely, it is possible that reactivation events contribute to changes in
neuronal size and number. Detection of extremely rare HSV-1
protein-expressing cells in a minority of TG at 12 and 31 weeks
after HSV-1 inoculation is consistent with virus reactivation.
However, potential causes of progressive neuronal injury are not
restricted to HSV-1 reactivation events, as latent infection and the
associated persistent inflammatory response also can cause neu-
ronal dysfunction and tissue injury (27, 37, 55, 57). Latent HSV-1
infection in the murine TG is associated with low-level expression
of replication-cycle HSV-1 genes in the absence of infectious virus
production (18). Marginal HSV-1 protein expression associated
with these incomplete reactivation attempts may induce neuronal
injury. Persistent inflammation during HSV-1 latency in the murine
TG also may cause neuronal injury, possibly mediated by cytokines
and oxidative stress (37, 55, 57). Indeed, the extent of neuronal
injury during latent infection in our current study seemed to corre-
late with the extent of inflammation in theTG (Table 3).These viral
and inflammatory processes may injure mature neurons or interfere
with ongoing neurogenesis and neuronal maturation in the TG.
While mice surviving the acute phase of experimental HSV
infection do not show signs and symptoms of encephalitis, numer-
ous studies documented chronic behavioral and neurological defi-
cits and chronic pain in these animals (1, 11, 34, 35, 43, 44, 51).
In the current study, mice were observed daily for signs and symp-
toms of encephalitis, but detailed neurological and behavioral
studies were not performed. Future experiments will need to deter-
mine whether HSV-1 latent infection-associated progressive patho-
logic changes documented here cause progressive neurological or
behavioral deficits in mice. These studies will provide an excellent
experimental platform to dissect mechanisms of HSV-induced
chronic neurological disease. A role for genetic susceptibility of
latent HSV-induced chronic neuronal injury should be a focus of
future studies using this experimental system as genetic suscepti-
bility has been repeatedly proposed to be important for the patho-
genesis of HSV-induced chronic neurological disease in humans
(5, 6, 16, 23, 28, 38, 45, 47, 61). These studies may lead to major
new insights into mechanisms by which latent viral infections
contribute to the pathogenesis of chronic neurological and neuro-
psychiatric diseases and foster development of virus-specific
intervention strategies.
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Identification of virus resistant tumor cell subpopulations in
three-dimensional uveal melanoma cultures
K Valyi-Nagy1, S Dosa1, SK Kovacs1, S Bacsa2, A Voros1, D Shukla2,3, R Folberg1 and
T Valyi-Nagy1
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To better understand melanoma resistance to herpes simplex virus type 1 (HSV-1)-mediated oncolysis, traditional two-dimensional
(2D) cultures and extracellular matrix (ECM) containing three-dimensional (3D) cultures of OCM1 and C918 uveal melanoma cells
were infected with an HSV-1 strain that expresses the green fluorescent protein (GFP) marker during replication. Although 2D
cultures were completely destroyed within a few days of HSV-1 inoculation, viable GFP-negative tumor cells remained detectable
in 3D cultures for several weeks. Tumor cells with increased resistance to HSV-1 included cells that formed vasculogenic mimicry
patterns and multicellular spheroids and cells that invaded Matrigel individually. Mechanisms of tumor resistance against HSV-1 in
the 3D environment included impaired virus spread in the ECM and ECM-mediated inhibition of viral replication after viral entry
into tumor cells. Observations also suggested that HSV-1 established quiescent infection in some tumor cells present in
multicellular spheroids and that this could revert to productive viral infection when the tumor growth pattern changed. These
findings indicate that 3D tumor cell cultures can be used to identify distinct tumor cell populations with increased resistance to
HSV-1 and to explore mechanisms of ECM-mediated tumor resistance to oncolytic virotherapy.
Cancer Gene Therapy (2010) 17, 223–234; doi:10.1038/cgt.2009.73; published online 6 November 2009
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Introduction
Virus, including herpes simplex virus type 1 (HSV-1)-
mediated oncolytic therapy, is a promising novel modality
of tumor therapy with potential usefulness against a wide
variety of malignancies.1–6 Oncolytic HSV-1 therapy is
dependent on virus replication in tumor cells and is
augmented by host antiviral and infection-induced
anti-tumor immune responses.7–11 In spite of significant
progress, oncolytic virotherapy faces significant chal-
lenges. Although traditional two-dimensional (2D) mono-
layer cultures of many types of tumor cells are efficiently
destroyed by a variety of HSV-1 vectors in vitro, tumor
destruction is often incomplete in vivo.1,7 Factors limiting
the effectiveness of HSV-1 oncolytic therapy in vivo
remain incompletely understood. However, observations
indicate that potential problems include the impairment
of intratumoral virus spread by the extracellular matrix
(ECM), decreased expression of viral entry receptors by
different tumor cell populations, activation of intracel-
lular tumor defenses to viral infection, and quick virus
clearance by the host immune system.7,12–19 It is clear that
many aspects of the complex virus–host interactions that
determine the effectiveness of HSV-1 oncolytic therapy
are difficult to impossible to study in traditional 2D tissue
culture systems.
The behavior of cells in vivo is controlled by their
interactions with neighboring cells and with the ECM.20–23
Cancer cells grown in three-dimensional (3D) cultures in a
polymeric ECM closely mimic the biology of tumor
development in vivo and numerous studies indicate that
3D cultures are superior to traditional 2D monolayer
cultures for studies of key cellular behaviors such as
differentiation, proliferation, invasion, and apoptosis.23–29
Cancer cells grown in 3D culture are more resistant to
chemotherapeutic agents and radiation than cells in 2D
culture and 3D tumor cell cultures are useful for preclinical
evaluation of the cytotoxic effect of anticancer agents.25,27,30
It is well established that multiple cell types within
individual tumors have differential sensitivities to drugs
and radiation both in vivo and in 3D cultures.25,27,30,31
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Although 3D cultures provide an excellent experimen-
tal system to study mechanisms of tumor cell resistance to
drugs and radiation, very few studies have used 3D tumor
cell cultures in the context of viral oncolytic ther-
apy.19,32,33 Earlier work in our laboratory indicated that
3D cultures of uveal melanoma cells show increased
resistance to HSV-1 relative to 2D cultures.33 Specifically,
destruction of 95% of tumor cells occurred several days
later in 3D cultures than in 2D cultures after HSV-1
inoculation. These findings suggested that HSV-1 inocu-
lation of 3D uveal melanoma cultures could provide a
useful model to study mechanisms of ECM-mediated
tumor resistance to HSV-1 oncolytic therapy.
The ECM environment is a critically important
determinant of the morphology and gene expression
profile of uveal melanomas in vivo and of uveal melanoma
cultures in vitro.34–39 Highly invasive uveal melanoma
cells, including C918 cells, and uveal melanoma cells of
low invasive potential, including OCM1 cells, all grow as
monolayers in 2D cultures. In 3D cultures established
with the use of laminin-rich ECM (Matrigel), highly
invasive uveal melanoma cells form vasculogenic mimicry
patterns. In contrast, uveal melanoma cells of low
invasive potential do not form vasculogenic mimicry
patterns under 3D conditions, but rather grow in tumor
cell aggregates on the matrix surface and form multi-
cellular spheroids inside the matrix. In addition to these
structures, 3D cultures of uveal melanoma cells contain a
variety of other morphologically distinguishable cell
populations that are defined by their spatial relationship
to the ECM. For instance, 3D cultures of both highly
invasive uveal melanoma cells and uveal melanoma cells
of low invasive potential contain individual tumor cells
invading the ECM. Observations indicate that morpho-
logically distinct tumor cell populations present in 3D
cultures are of clinical relevance. For instance, vasculo-
genic mimicry patterns are present in a wide variety of
malignancies including uveal melanomas and their detec-
tion is associated with increased mortality.34,37
This study has used 2D and 3D cultures of uveal
melanoma cells and was designed to find answers to the
following questions related to HSV-1 oncolytic therapy.
(i) Can 3D tumor cell cultures be used to identify
morphologically distinct tumor cell populations that have
increased resistance to HSV-1? (ii) Can 3D tumor cell
cultures be used to learn about mechanisms of ECM-
mediated tumor cell resistance to HSV-1 oncolytic
therapy?
We show here that 3D tumor cell cultures can be used
to identify distinct tumor cell populations with increased
resistance to HSV-1 oncolytic therapy. We report that
uveal melanoma cell populations with increased resistance
to HSV-1 in 3D cultures include cells forming vasculo-
genic mimicry patterns and multicellular spheroids and
tumor cells that invade the ECM individually. Further-
more, we show that mechanisms of tumor resistance
against HSV-1 in the 3D environment include impaired
virus spread in the Matrigel matrix and ECM-mediated
inhibition of viral replication after viral entry into tumor
cells.
Materials and methods
Viruses
Wild-type (wt) HSV-1 strain KOS and recombinant HSV-1
strain K26GFP (a gift from P Desai, The Johns Hopkins
University, Baltimore, MD) were amplified and quanti-
tated as described elsewhere.40,41 Cells infected with HSV-
1 strain K26GFP exhibit punctate nuclear fluorescence at
early times in the replication cycle and at later times
during infection, a generalized cytoplasmic and nuclear
fluorescence, including fluorescence at the cell membranes
can be observed.40 K26GFP was shown to grow wt virus
as well in cell culture.40
Cells
Uveal melanoma cells of low (OCM1) and high (C918)
invasive potential were maintained in Eagle’s Minimal
Essential Medium (BioWhittaker Inc., Walkersville, MD)
supplemented with heat inactivated 15% fetal bovine
serum (Fisher, Ontario, Canada) without the addition of
exogenous ECM molecules or growth factors. These cell
lines have been described in detail earlier.38,39,42
2D and 3D uveal melanoma cultures
Melanoma cells were grown on six-well plates in Eagle’s
Minimal Essential Medium medium either in the presence
(3D cultures) or in the absence (2D cultures) of ECM rich
in laminin (Matrigel, BD Biosciences, Bedford, MA). For
3D cultures, Matrigel was poured onto tissue culture
plates to a depth of approximately 0.2mm followed by
polymerization for 1 h at 37 1C before placement of
melanoma cells on the Matrigel surface. Cultures were
incubated in repeatedly refreshed culture medium for up
to 4 weeks and observed daily under an inverted
microscope (Leica, Bannockburn, IL).
Determination of susceptibility of uveal melanoma cells
to wt HSV-1 (KOS) and HSV-1 K26GFP-mediated
destruction in 2D and 3D cultures
C918 and OCM1 uveal melanoma cells were grown on
six-well tissue culture plates in the presence (3D cultures)
or absence of Matrigel (2D cultures). After 3–4 days,
when in the 3D cultures C918 cells formed prominent
vasculogenic mimicry patterns and OCM-1 cells formed
cell aggregates on the Matrigel surface and both cell lines
showed invasion of tumor cells into the Matrigel matrix,
the tissue culture medium was removed and one of the
following inocula was gently placed on the surface of the
cultures: (i) 0.5ml of sterile PBS (mock infection); (ii) wt
HSV-1 (strain KOS) with a calculated multiplicity of
infection (MOI) of 0.5 plaque forming units (PFU) per
cell diluted in PBS to a final volume of 0.5ml; (iii) HSV-1
K26GFP with a calculated MOI of 0.5 PFU per cell
diluted in PBS to a final volume of 0.5ml. After
incubation for 1 h, the original inocula were removed
and fresh tissue culture medium (3ml) was added to each
well and further incubated in repeatedly refreshed culture
medium for up to 4 weeks. During this 4-week period,
cultures were observed daily under an inverted fluores-
cence microscope (Leica, Bannockburn, IL) for evidence
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of viral cytopathic effects and green fluorescent protein
(GFP) expression. The day when at least 95% of the
melanoma cells were destroyed was noted. Cell death was
confirmed by the uptake of the charged cationic dye
Trypan blue (0.2%) by 495% of residual cells after
incubation of cultures with Trypan blue (0.2%) for 10min
at 37 1C.
Determination of HSV-1 spread through Matrigel
C918 and OCM1 uveal melanoma cells were grown on
12-well tissue culture plates in monolayers (2D cultures).
When the cultures have reached approximately 70%
confluency, culture media were removed and either 0.5ml
of a 1:1 mixture of PBS and Matrigel or 0.5ml of PBS was
layered on the cells. Cultures were then incubated at 37 1C
for 1 h to allow Matrigel to polymerize and form an
approximately 1mm thick layer matrix on the cells. Next,
cultures were either inoculated with 0.5ml HSV-1
K26GFP diluted in PBS to a calculated MOI of 0.5
PFU per cell or were mock infected with 0.5ml PBS by
gently layering these solutions on the cultures making
sure that the Matrigel surface was not violated. After
further incubation at 37 1C for 1 h, additional 2ml of
fresh tissue culture media was added to each well.
Cultures were then further incubated for up to 2 weeks
at 37 1C with fresh culture medium added to the cultures
every 2 days. During this 2-week period, cultures were
observed regularly under an inverted fluorescence micro-
scope (Leica, Bannockburn, IL) for evidence of GFP
expression.
Placement and culturing of earlier HSV-1 inoculated
uveal melanoma cells in 2D or 3D environments
C918 and OCM1 uveal melanoma cells were grown on
12-well tissue culture plates in monolayers (2D cultures).
When the cultures have reached approximately 70%
confluency, culture media were removed and the cells
were exposed at 37 1C to one of the following inocula: (i)
0.5ml of sterile PBS (mock infection) or (ii) HSV-1
K26GFP with a calculated MOI of 0.5 PFU per cell
diluted in PBS to a final volume of 0.5ml. After
incubation for 1 h, the original inocula were removed
and the monolayers were washed in sterile PBS twice and
1ml of sterile PBS was added to each well. Cells were than
scraped off using sterile, disposable cell scrapers. Cell
solutions were than centrifuged and cell pellets were
resuspended in culture medium. Equal volumes (0.25ml)
of the cell solutions were then used to either establish
new 2D cultures in 12-well tissue culture plates or 3D
cultures as follows. For 3D cultures, Matrigel was poured
onto tissue culture plates to a depth of approximately
0.2mm followed by polymerization for 1 h at 37 1C
Cell suspensions of HSV-1 K26GFP or mock-infected
uveal melanoma cells were mixed with Matrigel 1:1
(0.25:0.25ml) and poured on the Matrigel-coated wells.
Finally, 2ml of fresh culture medium was added. 2D and
3D cultures were then further incubated for up to 4 weeks
at 37 1C with fresh culture medium added to the cultures
every 2 days. During this 4-week period, cultures
were observed regularly under an inverted fluorescence
microscope (Leica, Bannockburn, IL) for evidence of
GFP expression and the percentage of GFP-expressing
cells was determined by counting the number of GFP-
positive and GFP-negative cells in 16 high power
microscopic fields for each studied type of treatment at
selected time points.
Results
OCM1 and C918 uveal melanoma cells form several
morphologically distinct cell populations under 3D
culture conditions
To define in detail the growth pattern of uveal melanoma
cells in 2D and 3D cultures, OCM1 and C918 cells were
grown either in the presence or absence of laminin-rich
ECM (Matrigel). In the absence of Matrigel (2D cultures),
both OCM1 and C918 grew in monolayers (Figure 1a and
b). In the presence of Matrigel, both cell lines developed
3D structures (Figures 1c–h. 2a–d, 3a–d). When OCM1
cells were placed on the Matrigel surface, the cells first
formed aggregates that were loosely attached to the
Matrigel surface (Figures 1c, 2a). As the cell aggregates
were growing further, their attachment to the Matrigel
surface became wider and firmer and single tumor cells
began to invade the Matrigel matrix (Figure 2a and b).
During further growth, individual tumor cells invaded the
matrix deeply and some of these cells formed multicellular
spheroids showing a smooth surface and consisting of
cells tightly attached to each other (Figures 1e, 2c).
Tumor cell aggregates on the Matrigel surface also
showed similar spheroid formation at their bottom
portion that completely immersed in the Matrigel matrix
(Figure 2b and c). Many of the tumor cell spheroids were
stable for days to weeks, whereas others showed out-
growth of individual cells into the matrix. Cells invading
the matrix (Figure 1g) eventually reached the bottom of
the tissue culture plate and grew under the matrix in
monolayers (Figure 2d). The growth of OCM1 cells
within the Matrigel matrix did not cause massive
destruction of the matrix until the end of the 4-week
observation period.
When C918 cells were placed on the Matrigel surface,
the cells started to grow on the matrix surface in a single
layer and formed circular vasculogenic mimicry patterns
that surrounded round matrix surfaces free of tumor cells
(Figures 1d, 3a). Next, individual tumor cells started to
grow into the Matrigel at the line defined by the
vasculogenic mimicry patterns (Figures 1f, 3b). Cells
invading the matrix migrated to the bottom of the culture
plate and formed monolayers there (Figures 1h, 3c
and d). Interestingly, the formation of these bottom
monolayers was restricted to areas that were under the
Matrigel surfaces that were not colonized by cells and
were surrounded by vasculogenic mimicry patterns
(Figure 3c). Next, individual tumor cells invaded the
matrix underlying cell monolayers on the Matrigel surface
(Figure 3d). Tumor cell growth and matrix invasion
eventually caused a loss of Matrigel in areas surrounded
by vasculogenic mimicry patterns (Figure 3d).
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These observations confirm and extend earlier observa-
tions related to the morphology uveal melanoma
cultures38 and indicate that OCM1 and C918 uveal
melanoma cells form several morphologically distinct cell
populations under 3D culture conditions.
Rapid destruction of 2D and delayed and incomplete
destruction of 3D uveal melanoma cultures by wt
HSV-1 and HSV-1 K26GFP
2D and 3D cultures of OCM1 and C918 cells were
inoculated with wt HSV-1 strain KOS or HSV-1 strain
Figure 1 Morphology of OCM1 and C918 uveal melanoma cells grown in either 2D or 3D cultures. OCM1 cells grown in 2D monolayers for
5 days (a). Five-day-old 3D OCM1 culture. Arrow indicates surface aggregate of cells (c). Same 3D OCM1 culture with focus deeper on
multicellular spheroid (arrow) within Matrigel (e). Same 3D OCM1 culture with focus even deeper on individual tumor cells (arrows) invading
Matrigel (g). C918 cells grown in 2D monolayers for 5 days (b). Three-day-old 3D C918 culture with focus on Matrigel surface. Arrow indicates
vasculogenic mimicry forming cells and asterix marks tumor cells growing in monolayer on Matrigel surface (d). Same 3D C918 culture with focus
on tumor cells (arrow) invading the Matrigel matrix (f). Six-day-old 3D C918 culture with focus on tumor cells growing in monolayer under the
Matrigel matrix (h).
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K26GFP by placing virus solutions on the surface of the
cultures. HSV-1 K26GFP exhibits fluorescence on replica-
tion.40 Cultures were followed for evidence of cytopathic
effects and virus replication (GFP expression/fluorescence)
by an inverted fluorescence microscope.
We found that 2D cultures were completely destroyed
by both HSV-1 strains within a few days (Table 1) with no
evidence of surviving cells by Trypan blue staining (data
not shown). In contrast, virus inoculated 3D cultures
showed delayed and incomplete destruction (Table 1).
Importantly, a portion of both OCM1 and C918 cells
seemed to survive HSV-1 KOS and HSV-1 K26GFP
infection in 3D cultures for up to 4 weeks. Cell
populations with increased resistance included C918 cells
that formed vasculogenic mimicry patterns on the
Matrigel surface, OCM1 cells that formed multicellular
spheroids within the Matrigel matrix, and both C918 and
OCM1 cells that invaded Matrigel individually.
In K26GFP inoculated 2D OCM1 and C918 cultures,
20–50% of tumor cells showed GFP expression by 1 day
post infection (p.i.), and after 3 days p.i., it was very
difficult to find any cells without fluorescence consistent
with the complete viral replication-mediated destruction
of these cultures by 4–5 days (Figures 4a and b, 6a and b).
In contrast, 3D cultures of both OCM1 and C918
showed a significant number of GFP-negative cells
throughout the 4-week observation period (Figures
4c–h, 5a–f, 6c–h, 7a–f).
In 3D cultures of OCM1, cells forming aggregates on
the Matrigel surface showed widespread fluorescence
(virus replication) by 1 day p.i., and after 4 days p.i., it
was very difficult to find any cells without fluorescence in
these structures consistent with the complete virus-
mediated destruction of these surface cell aggregates by
K26GFP by 8 days p.i. (Figure 4c and d). Individual
OCM1 cells growing into the Matrigel matrix showed
variable fluorescence and some apparently viable, and
GFP-negative cells were consistently present during the
4-week observation period. Cells forming multicellular
spheroids inside the matrix and cells forming spheroids at
the bottom, matrix immersed portion of surface aggre-
gates showed marked resistance to HSV-1 replication
(Figures 4c–h, 5a and b). Although occasional spheroids
showed widespread fluorescence by 4 days p.i., others
contained only a few GFP-positive cells and many
remained completely devoid of GFP expression for days
to weeks. GFP-negative spheroids contained viable cells
as radial outgrowth of individual cells into the Matrigel
matrix was observed from many of these structures as the
cultures were aging (Figure 5a,c and e). Interestingly, this
outgrowth was often associated with the appearance of
fluorescence in outgrowing cells and in cells within the
spheroids (Figure 5d and f), whereas in other cases, both
spheroids and outgrowing cells remained GFP negative
(Figure 5b). Cells growing under the matrix in monolayers
were susceptible to HSV-1 and showed widespread
fluorescence.
In 3D cultures of C918 cells, cells growing on the
matrix surface in a single layer showed widespread
fluorescence (virus replication) as early as 1 day p.i.
consistent with the complete destruction of this cell
population by K26GFP by 9 days p.i. (Figure 6c and
d). In contrast, cells forming vasculogenic mimicry
Figure 2 Schematic illustration of the morphology of 2-day-old (a),
3-day-old (b), 4-day-old (c), and 5-day-old (d) 3D OCM1 uveal
melanoma cultures. 1, cells forming aggregates on Matrigel surface;
2, individual cells invading Matrigel; 3, multicellular spheroids at the
bottom portion of aggregates immersed into the Matrigel; 4, tumor
cell spheroid within Matrigel not associated with surface aggregates;
and 5, tumor cells growing in monolayers under the Matrigel on the
surface of the culture dish.
Figure 3 Schematic illustration of the morphology of 2-day-old (a),
3-day-old (b), 4-day-old (c), and 5-day-old (d) 3D C918 uveal
melanoma cultures. 1 (cells marked dark), cells forming vasculo-
genic mimicry patterns on the Matrigel surface; 2, cells forming
monolayers on the Matrigel surface; 3, individual tumor cells invading
Matrigel and growing toward the bottom of the culture dish; 4, tumor
cells growing in monolayers under the Matrigel in the center of
vasculogenic mimicry patterns; and 5, individual tumor cells invading
Matrigel underlying cell monolayers on the Matrigel surface.
Table 1 Elapsed time from inoculation of HSV-1 KOS or HSV-1
K26GFP (at MOI¼ 0.5 PFU per cell) to at least 95% destruction of
2D and 3D OCM1 and C918 uveal melanoma cultures
Cell line Culture
condition
HSV-1 strain Day of 95%
destruction
OCM1 2D KOS 4
3D KOS 8
2D K26GFP 4
3D K26GFP 8
C918 2D KOS 5
3D KOS 9
2D K26GFP 5
3D K26GFP 9
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patterns on the Matrigel surface showed increased
resistance to HSV-1 (Figure 6e and f) and GFP-negative
cells could be observed in these structures throughout the
4-week observation period. Similarly, cells invading the
matrix individually showed increased resistance to HSV-1
and this cell population also included many GFP-negative
cells throughout the 4-week observation period (Figures
6g–h, 7a–f). Tumor cells growing in monolayers under the
Matrigel showed widespread fluorescence and suscept-
ibility to HSV-1 (Figure 6e and f).
These observations clearly identify certain uveal mela-
noma populations with increased resistance against HSV-1
in the 3D environment. Consequent experiments were
designed to identify the mechanism(s) responsible for the
Figure 4 Morphology and GFP expression in HSV-1 K26GFP inoculated OCM1 uveal melanoma 2D and 3D cultures. 2D OCM1 culture 1 day
after virus inoculation; morphology (a) and GFP expression (b). 3D OCM1 cultures 1 day after virus inoculation; morphology (c) and GFP
expression (d). Arrows in panel (c) indicate tumor cell aggregates on the Matrigel surface that are GFP positive in panel D and arrowhead in
panel C indicates a multicellular spheroid within the Matrigel matrix that is GFP negative in panel D. 3D OCM1 cultures 3 days after virus
inoculation; morphology (e) and GFP expression (f). Arrowhead in panel E indicates a multicellular spheroid within the Matrigel matrix that is GFP
negative in panel F. 3D OCM1 cultures 12 days after virus inoculation; morphology (g) and GFP expression (h). Arrowhead in panel G indicates a
multicellular spheroid within the Matrigel matrix showing outgrowth of individual tumor cells at the periphery that is GFP negative in panel H.
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observed resistance of tumor cells against HSV-1 in 3D
cultures.
Matrigel impairs HSV-1 spread
To determine whether inhibition of HSV-1 spread
through Matrigel was a mechanism responsible for the
absence of virus replication (GFP expression) in some
tumor cells in 3D cultures, monolayers of OCM1 and
C918 cells were covered with an approximately 1mm
thick layer of Matrigel and then HSV-1 K26GFP was
placed on the Matrigel surface. As controls, monolayers
of OCM and C918 cells without a Matrigel cover were
also inoculated with the same amount of virus. Virus
inoculated uveal monolayers with no Matrigel cover
showed widespread GFP expression by 18–24 h p.i. and
were completely destroyed within a few days. In contrast,
cells covered with Matrigel and inoculated with HSV-1
K26GFP showed continued viability and growth during a
2-week observation period with no evidence of GFP
expression. These findings indicate that Matrigel inhibits
HSV-1 spread.
ECM mediates inhibition of HSV-1 replication after virus
entry into tumor cells
To determine whether inhibition of viral replication after
virus entry into tumor cells is a mechanism responsible for
the absence of virus replication (GFP expression) in some
tumor cells in 3D cultures, uveal melanoma cells were first
inoculated with HSV-1 K26GFP under 2D conditions
(allowing for unimpeded entry of virus into cells) and
were then cultured under either 2D or 3D conditions.
Briefly, C918 and OCM1 uveal melanoma cells grown in
monolayers were either exposed to HSV-1 K26GFP at a
calculated MOI of 0.5 PFU per cell or to sterile PBS
(mock infection) for 1 h. The original inocula were then
removed and the inoculated cells were scraped off and
were resuspended in fresh culture medium. Equal volumes
of the cell solutions were then used to either establish new
Figure 5 Morphology and GFP expression in HSV-1 K26GFP inoculated 3D OCM1 uveal melanoma cultures 12 days after virus inoculation.
Arrowhead in panel (a) indicates a multicellular spheroid within the Matrigel matrix that shows outgrowth of individual tumor cells at its periphery
that are GFP negative in panel (b). Arrowhead in panel (c) indicates a multicellular spheroid within the Matrigel matrix showing outgrowth of
individual tumor cells. Some of the outgrowing tumor cells show GFP expression in panel (d). Arrowhead in panel (e) indicates a multicellular
spheroid within the Matrigel matrix with outgrowth of individual tumor cells at the periphery with cells within the core of the spheroid showing GFP
expression in panel (f).
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2D or 3D cultures. For 3D cultures, cell suspensions of
HSV-1 K26GFP or mock-infected uveal melanoma cells
were mixed with Matrigel 1:1 and these mixtures were
poured on earlier Matrigel-coated tissue culture plates.
After the plating of earlier mock-infected OCM1 and
C918 cells on tissue culture dishes, tumor cells established
monolayers (2D cultures) that showed normal growth and
no evidence of GFP expression. Growing of earlier mock-
infected OCM1 and C918 cells under 3D conditions in
Matrigel was initially associated with single cells sus-
pended in matrix. After the first day, growth of OCM1
cells was associated with the development of tumor cell
spheroids, many of which later showed outgrowth of
individual cells into the matrix. Growth of mock-infected
Figure 6 Morphology and GFP expression in HSV-1 K26GFP inoculated C918 uveal melanoma cells grown in 2D and 3D cultures. 2D C918
monolayer culture 3 days after virus inoculation; morphology (a) and GFP expression (b). 3D C918 culture 3 days after virus inoculation;
morphology (c) and GFP expression (d). Arrow in panel (c) indicates tumor cells growing in monolayer on the Matrigel surface that express GFP
in panel (d). 3D C918 culture 3 days after virus inoculation; morphology (e) and GFP expression (f). Arrow in panel (e) indicates tumor cells
forming vasculogenic mimicry pattern on the Matrigel surface that only partially expresses GFP in panel (f). 3D C918 culture 3 days after virus
inoculation; morphology (g) and GFP expression (h). Arrow in panel (g) indicates a tumor cell invading Matrigel that does not express GFP in
panel (h). Arrowhead in panel (g) indicates a tumor cell invading Matrigel that expresses GFP in panel (h).
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C918 cells was associated with the establishment of
extensive network of tumor cells invading the matrix.
No GFP expression was detected in the mock-infected 3D
cultures of OCM1 and C918 cells.
After the plating of earlier HSV-1 K26GFP inoculated
OCM1 and C918 cells on tissue culture dishes, tumor cells
established monolayers (2D cultures) that were comple-
tely destroyed by virus replication within a few days.
At 18 h p.i., 29.53±15.01% of OCM1 cells and 40.33±
15.17% of C918 cells showed fluorescence (evidence of
HSV-1 replication) (Table 2). Nearly all OCM1 cells were
GFP positive by 72 h and nearly all C918 cells were GFP
positive by 96 h. These findings are consistent with
replication of input virus in infected cells at 18 h p.i.
and virus spread to all cells in the following days.
Culturing of earlier HSV-1 K26GFP inoculated OCM1
and C918 cells in 3D was initially associated with single
cells suspended in matrix. More than half of the cells
showed morphologic changes during the first day of the
establishment of the 3D cultures including rounding and a
minority of cells showed morphological features of
apoptosis. At 18 h p.i., the numbers of OCM1 and C918
cells in the virus-infected 3D cultures were 12.5 and
8.5% lower than those in their mock-infected 3D
counterparts. At 18 h p.i., 2.80±2.75% of OCM1 cells
Figure 7 Morphology (a, c, e) and GFP expression (b, d, f) of cells invading the Matrigel matrix in HSV-1 K26GFP inoculated 3D C918 uveal
melanoma cultures 12 days after virus inoculation. Note the lack of GFP expression in panels (b, d) and the variable expression of GFP by tumor
cells in panel (f).
Table 2 GFP expression in OCM1 and C918 uveal melanoma cells
inoculated with 0.5 PFU per cell of HSV-1 K26GFP or mock infected
with PBS under 2D conditions for 1 h and then cultured for 17 h either
under 2D or 3D conditions
Cell line Inoculation in 2D Consequent
culture
Percent of cells
GFP +a
OCM1 mock 2D 0
HSV-1 K26GFP 2D 29.53±15.01
mock 3D 0
HSV-1 K26GFP 3D 2.8±2.75
C918 mock 2D 0
HSV-1 K26GFP 2D 40.33±15.17
mock 3D 0
HSV-1 K26GFP 3D 2.22±3.05
aPercentage of GFP-expressing cells was determined by
counting the number of GFP-expressing and GFP-negative cells
in 16 high power microscopic fields for each studied type of
treatment.
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and 2.22±3.05% of C918 cells showed fluorescence
(Table 2) in the HSV-1-infected 3D cultures. The number
of GFP-expressing cells did not increase the following
days. Thus, at 18 h p.i., a significantly smaller percentage
of cells showed evidence of virus replication in 3D
cultures than what was expected on the basis of the
amount of input virus. These observations indicate that
the ECM can mediate the inhibition of HSV-1 replication
after virus entry into tumor cells.
In HSV-1-infected 3D cultures, the majority of cells
remained GFP negative throughout a 4-week observation
period (data not shown). Interestingly, the outgrowth of
individual OCM1 cells into the Matrigel matrix from
spheroids that have been GFP negative for days to weeks
was occasionally associated with the appearance of GFP
expression in outgrowing cells and in cells within the
spheroids similarly to the process shown in Figure 5c–f.
As Matrigel does not allow HSV-1 spread, these obser-
vations suggest that HSV-1 established a quiescent
infection in some tumor cells within multicellular spher-
oids and that this quiescent infection could revert to
productive viral infection when the tumor growth pattern
changed.
Discussion
We show here for the first time that 3D tumor cell
cultures can be used to identify morphologically distinct
tumor cell populations with increased resistance to
HSV-1. Specifically, we show that tumor cells forming
vasculogenic mimicry patterns and multicellular spheroids
and cells that invade the ECM individually have increased
resistance to HSV-1. Furthermore, we show that mechan-
isms of tumor resistance against HSV-1 in the 3D
environment include impaired virus spread in the ECM
and ECM-mediated inhibition of viral replication after
viral entry into tumor cells. Observations reported here
also suggest that HSV-1 can establish quiescent infection
in some tumor cells present in multicellular spheroids and
that this can revert to productive viral infection on
outgrowth of individual tumor cells into the Matrigel
matrix.
It is well established that 3D tumor cell cultures are
useful for preclinical evaluation of the cytotoxic effect of
anticancer agents, and multiple cell types within indivi-
dual tumors have differential sensitivities to drugs and
radiation both in vivo and in 3D cultures.25,27,30,31
However, so far very few studies have used 3D tumor
cell cultures in the context of viral oncolytic therapy.
These studies have indicated that tumor cells grown in 3D
cultures are also more resistant to viral, including HSV-1
and adenovirus-mediated oncolytic therapy, than cells
grown in 2D culture.32,33 Observations reported here
confirm and extend these studies and identify morpholo-
gically distinct tumor cell populations present in 3D
cultures that have increased resistance to viral oncolytic
therapy. These observations are likely of clinical relevance
as, for instance, vasculogenic mimicry patterns are present
in a wide variety of malignancies and their detection in
several tumor types is associated both with adverse
outcome.34,37
Factors limiting the effectiveness of HSV-1 oncolytic
therapy remain poorly understood in part because related
studies have been limited to expensive and time-consum-
ing experimental animal models. Theoretical considera-
tions and experimental observations made thus far
indicate that mechanisms of tumor resistance to HSV-1
therapy include ECM-mediated impairment of intratu-
moral virus spread, impaired viral entry into tumor
cells because of decreased expression of HSV-1 entry
receptors, inhibition of viral replication after viral entry
into tumor cells, and virus clearance by the host immune
system.5–7,12–15,17–18 In this study, we found that at least
two of these potential mechanisms of virus resistance—
impaired virus spread in the ECM and inhibition of viral
replication after viral entry into tumor cells—are also
relevant to 3D tumor cell cultures.
HSV-1 oncolysis can be improved by degradation of
fibrillar collagen in tumors indicating that the ECM has
an important function in determining treatment effi-
cacy.15 This study indicates that laminin-rich ECM,
Matrigel inhibits HSV-1 spread. These findings are
consistent with the earlier reported inhibition of HSV-1
spread by epithelial basement membrane in vivo and by
Matrigel in vitro.43 It is important to note that HSV-1
could clearly infect and replicate in some uveal melanoma
cells that have invaded the Matrigel matrix in this study.
These observations indicate that HSV-1 can spread
through Matrigel if tumor cells infiltrating the ECM are
present. Whether HSV-1 can spread from cell to cell
within the Matrigel matrix through intercellular contacts
or through spaces in Matrigel created by growing tumor
cells remains unclear at this point.
This study also indicates that inhibition of viral
replication at a stage beyond viral entry is an important
mechanism by which the ECM can modulate viral
replication in tumors. It is well known that adhesion of
cancer cells to the ECM mediates drug and radiation
resistance.27,29,44 The connection of tumor cells to ECM
proteins such as collagen and laminin through cell
adhesion molecules, in particular integrin receptors, is
associated with tumor cell survival and drug resistance
through the activation of a variety of signaling pathways.
It is unclear at this point to what extent, if any,
mechanisms of drug and radiation resistance in 3D tumor
cell cultures are overlapping with mechanisms of virus
resistance. It is possible that ECM-mediated signaling
affects the expression of cellular transcription factors that
can regulate the expression of viral genes in a manner that
is not favorable for the progression of the viral replication
cycle after HSV-1 entry.
Interestingly, observations made in this study suggest
that HSV-1 establishes quiescent infection in some tumor
cells in 3D cultures. When OCM1 and C918 cells were
inoculated with HSV-1 under 2D conditions and were
then cultured within Matrigel, only a small minority of
tumor cells that have taken up HSV-1 showed evidence of
virus replication (GFP expression). As discussed earlier,
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these findings indicated that the viral replication cycle was
inhibited at a post-entry step in the majority of infected
tumor cells. Consequent growth of virus inoculated
OCM1 cells in 3D cultures was associated with the
establishment of multicellular tumor cell spheroids. Many
OCM1 cells forming multicellular spheroids remained
GFP negative throughout a 4-week observation period.
However, the outgrowth of individual OCM1 cells into
the Matrigel matrix from spheroids that have been GFP
negative for days to weeks was often associated with the
appearance of GFP expression in outgrowing cells and in
cells within the spheroids. As Matrigel inhibits virus
spread, reappearance of GFP expression in multicellular
spheroids was very suggestive of virus reactivation from
quiescence in earlier HSV-1 inoculated cells. It is well
known that HSV-1 can establish quiescent infection in
cultured non-neuronal cells if the progression of the viral
replication cycle is blocked shortly after virus entry.45,46
However, establishment of quiescent infection in tumor
cells induced by the ECM environment and reactivation
of viral replication on changing tumor growth pattern
have not been yet been reported. It will be of practical
significance to determine whether similar processes also
occur in vivo during HSV-1 oncolytic therapy.
In summary, observations reported here provide novel
information about virus resistance of distinct tumor cell
subpopulations in 3D tumor cell cultures and about
mechanisms of ECM-mediated virus resistance of tumor
cells. It is clear that additional studies will be required to
fully understand the mechanisms by which the ECM
mediates increased HSV-1 resistance of tumor cells in 3D
cultures and to assess the clinical relevance of information
collected in these cultures. However, our observations
suggest that the experimental platform provided by 3D
tumor cultures will be invaluable for studies aimed at the
improvement and preclinical evaluation of viral oncolytic
agents similarly to its usefulness in the case of chemother-
apeutic agents and radiation therapy.
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